ZA200605340B - DNA damage repair inhibitors for treatment of cancer - Google Patents
DNA damage repair inhibitors for treatment of cancer Download PDFInfo
- Publication number
- ZA200605340B ZA200605340B ZA200605340A ZA200605340A ZA200605340B ZA 200605340 B ZA200605340 B ZA 200605340B ZA 200605340 A ZA200605340 A ZA 200605340A ZA 200605340 A ZA200605340 A ZA 200605340A ZA 200605340 B ZA200605340 B ZA 200605340B
- Authority
- ZA
- South Africa
- Prior art keywords
- cancer
- parp inhibitor
- parp
- individual
- cells
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 139
- 201000011510 cancer Diseases 0.000 title claims description 118
- 239000003112 inhibitor Substances 0.000 title claims description 49
- 238000011282 treatment Methods 0.000 title claims description 41
- 230000005971 DNA damage repair Effects 0.000 title description 2
- 108020004414 DNA Proteins 0.000 claims description 115
- 230000008439 repair process Effects 0.000 claims description 94
- 230000002950 deficient Effects 0.000 claims description 88
- 230000001419 dependent effect Effects 0.000 claims description 88
- 230000037361 pathway Effects 0.000 claims description 69
- 239000012661 PARP inhibitor Substances 0.000 claims description 68
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 claims description 68
- 101150008921 Brca2 gene Proteins 0.000 claims description 64
- 230000000694 effects Effects 0.000 claims description 57
- 238000000034 method Methods 0.000 claims description 54
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 claims description 47
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 claims description 47
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims description 45
- 230000035772 mutation Effects 0.000 claims description 37
- 150000007523 nucleic acids Chemical group 0.000 claims description 36
- 102000052609 BRCA2 Human genes 0.000 claims description 32
- 108700020462 BRCA2 Proteins 0.000 claims description 32
- 108090000623 proteins and genes Proteins 0.000 claims description 29
- 102000039446 nucleic acids Human genes 0.000 claims description 26
- 108020004707 nucleic acids Proteins 0.000 claims description 26
- 101100300807 Drosophila melanogaster spn-A gene Proteins 0.000 claims description 13
- 230000015572 biosynthetic process Effects 0.000 claims description 13
- 102000054765 polymorphisms of proteins Human genes 0.000 claims description 12
- 230000002829 reductive effect Effects 0.000 claims description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- IJAPPYDYQCXOEF-UHFFFAOYSA-N phthalazin-1(2H)-one Chemical class C1=CC=C2C(=O)NN=CC2=C1 IJAPPYDYQCXOEF-UHFFFAOYSA-N 0.000 claims description 9
- 108010033276 Peptide Fragments Proteins 0.000 claims description 8
- 102000007079 Peptide Fragments Human genes 0.000 claims description 8
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims description 8
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 8
- 230000030833 cell death Effects 0.000 claims description 8
- VDBNYAPERZTOOF-UHFFFAOYSA-N isoquinolin-1(2H)-one Chemical class C1=CC=C2C(=O)NC=CC2=C1 VDBNYAPERZTOOF-UHFFFAOYSA-N 0.000 claims description 8
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 8
- 230000000295 complement effect Effects 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 239000002246 antineoplastic agent Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 230000004044 response Effects 0.000 claims description 6
- 239000012623 DNA damaging agent Substances 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 229940054066 benzamide antipsychotics Drugs 0.000 claims description 5
- 150000003936 benzamides Chemical class 0.000 claims description 5
- 229940127089 cytotoxic agent Drugs 0.000 claims description 5
- AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical class C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 claims description 4
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims description 4
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 150000001556 benzimidazoles Chemical class 0.000 claims description 4
- 150000008375 benzopyrones Chemical class 0.000 claims description 4
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims description 4
- 210000000481 breast Anatomy 0.000 claims description 4
- 229960001948 caffeine Drugs 0.000 claims description 4
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 4
- 150000002475 indoles Chemical class 0.000 claims description 4
- PXZQEOJJUGGUIB-UHFFFAOYSA-N isoindolin-1-one Chemical class C1=CC=C2C(=O)NCC2=C1 PXZQEOJJUGGUIB-UHFFFAOYSA-N 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 235000005152 nicotinamide Nutrition 0.000 claims description 4
- 150000005480 nicotinamides Chemical group 0.000 claims description 4
- 210000000496 pancreas Anatomy 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 150000005053 phenanthridines Chemical class 0.000 claims description 4
- 230000008685 targeting Effects 0.000 claims description 4
- 229960000278 theophylline Drugs 0.000 claims description 4
- 229940104230 thymidine Drugs 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 3
- 210000001672 ovary Anatomy 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 description 160
- 230000005782 double-strand break Effects 0.000 description 77
- 230000006801 homologous recombination Effects 0.000 description 67
- 238000002744 homologous recombination Methods 0.000 description 67
- 230000033590 base-excision repair Effects 0.000 description 41
- 239000000306 component Substances 0.000 description 38
- 150000001875 compounds Chemical class 0.000 description 34
- 239000000523 sample Substances 0.000 description 30
- 230000005764 inhibitory process Effects 0.000 description 22
- 230000014509 gene expression Effects 0.000 description 19
- 239000000203 mixture Substances 0.000 description 18
- -1 5-substituted dihydroisoquinolinones Chemical class 0.000 description 13
- 108020004459 Small interfering RNA Proteins 0.000 description 13
- 238000009472 formulation Methods 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 230000035945 sensitivity Effects 0.000 description 12
- 230000027455 binding Effects 0.000 description 11
- 238000003752 polymerase chain reaction Methods 0.000 description 10
- 229920001184 polypeptide Polymers 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 230000009368 gene silencing by RNA Effects 0.000 description 9
- 238000009396 hybridization Methods 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 108091060290 Chromatid Proteins 0.000 description 8
- 239000000969 carrier Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 229930189065 blasticidin Natural products 0.000 description 7
- 210000004756 chromatid Anatomy 0.000 description 7
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000003321 amplification Effects 0.000 description 6
- 230000000692 anti-sense effect Effects 0.000 description 6
- 210000000349 chromosome Anatomy 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 102100023652 Poly [ADP-ribose] polymerase 2 Human genes 0.000 description 5
- 102000001195 RAD51 Human genes 0.000 description 5
- 108010068097 Rad51 Recombinase Proteins 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000005025 clonogenic survival Effects 0.000 description 5
- 238000003927 comet assay Methods 0.000 description 5
- 108010045262 enhanced cyan fluorescent protein Proteins 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 230000005783 single-strand break Effects 0.000 description 5
- 231100000188 sister chromatid exchange Toxicity 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 230000005778 DNA damage Effects 0.000 description 4
- 231100000277 DNA damage Toxicity 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000013000 chemical inhibitor Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- QMNUDYFKZYBWQX-UHFFFAOYSA-N 1H-quinazolin-4-one Chemical class C1=CC=C2C(=O)N=CNC2=C1 QMNUDYFKZYBWQX-UHFFFAOYSA-N 0.000 description 3
- 102100027161 BRCA2-interacting transcriptional repressor EMSY Human genes 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 101150029113 EMSY gene Proteins 0.000 description 3
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102100033636 Histone H3.2 Human genes 0.000 description 3
- 108010033040 Histones Proteins 0.000 description 3
- 101001057996 Homo sapiens BRCA2-interacting transcriptional repressor EMSY Proteins 0.000 description 3
- 101001113440 Homo sapiens Poly [ADP-ribose] polymerase 2 Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 3
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 3
- 125000005488 carboaryl group Chemical group 0.000 description 3
- 229960004562 carboplatin Drugs 0.000 description 3
- 229960004316 cisplatin Drugs 0.000 description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
- 238000009643 clonogenic assay Methods 0.000 description 3
- 231100000096 clonogenic assay Toxicity 0.000 description 3
- 231100000170 comet assay Toxicity 0.000 description 3
- 239000013068 control sample Substances 0.000 description 3
- 239000003431 cross linking reagent Substances 0.000 description 3
- 229960004397 cyclophosphamide Drugs 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000030279 gene silencing Effects 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229960004857 mitomycin Drugs 0.000 description 3
- 230000000394 mitotic effect Effects 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 239000002751 oligonucleotide probe Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 2
- JJDMKDXGNVJWCD-UHFFFAOYSA-N 1h-benzimidazole-4-carboxamide Chemical class NC(=O)C1=CC=CC2=C1N=CN2 JJDMKDXGNVJWCD-UHFFFAOYSA-N 0.000 description 2
- HXTDAUGEZTYMGP-UHFFFAOYSA-N 6-nitrosochromen-2-one Chemical compound O1C(=O)C=CC2=CC(N=O)=CC=C21 HXTDAUGEZTYMGP-UHFFFAOYSA-N 0.000 description 2
- 239000012827 ATM inhibitor Substances 0.000 description 2
- IGAZHQIYONOHQN-UHFFFAOYSA-N Alexa Fluor 555 Chemical compound C=12C=CC(=N)C(S(O)(=O)=O)=C2OC2=C(S(O)(=O)=O)C(N)=CC=C2C=1C1=CC=C(C(O)=O)C=C1C(O)=O IGAZHQIYONOHQN-UHFFFAOYSA-N 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 2
- 238000011728 BALB/c nude (JAX™ mouse strain) Methods 0.000 description 2
- 101100407073 Caenorhabditis elegans parp-1 gene Proteins 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 108090000323 DNA Topoisomerases Proteins 0.000 description 2
- 102000003915 DNA Topoisomerases Human genes 0.000 description 2
- 230000000970 DNA cross-linking effect Effects 0.000 description 2
- 230000033616 DNA repair Effects 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- YJDAOHJWLUNFLX-UHFFFAOYSA-N NU 1025 Chemical compound C1=CC=C2C(=O)NC(C)=NC2=C1O YJDAOHJWLUNFLX-UHFFFAOYSA-N 0.000 description 2
- 108700019961 Neoplasm Genes Proteins 0.000 description 2
- 102000048850 Neoplasm Genes Human genes 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 101710126859 Single-stranded DNA-binding protein Proteins 0.000 description 2
- 206010043276 Teratoma Diseases 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000025084 cell cycle arrest Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- SFZULDYEOVSIKM-UHFFFAOYSA-N chembl321317 Chemical compound C1=CC(C(=N)NO)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=N)NO)O1 SFZULDYEOVSIKM-UHFFFAOYSA-N 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000002900 effect on cell Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 231100000225 lethality Toxicity 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000033607 mismatch repair Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000006780 non-homologous end joining Effects 0.000 description 2
- 230000020520 nucleotide-excision repair Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- RZFVLEJOHSLEFR-UHFFFAOYSA-N phenanthridone Chemical class C1=CC=C2C(O)=NC3=CC=CC=C3C2=C1 RZFVLEJOHSLEFR-UHFFFAOYSA-N 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 150000004892 pyridazines Chemical class 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 235000019527 sweetened beverage Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960000303 topotecan Drugs 0.000 description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 1
- AGPZUEDYVLUKMF-UHFFFAOYSA-N 1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one Chemical compound O=C1NCCC2=CNC3=CC=CC1=C23 AGPZUEDYVLUKMF-UHFFFAOYSA-N 0.000 description 1
- HZIDLPHYFPKXIE-UHFFFAOYSA-N 1,3-benzoxazole-4-carboxamide Chemical class NC(=O)C1=CC=CC2=C1N=CO2 HZIDLPHYFPKXIE-UHFFFAOYSA-N 0.000 description 1
- IPQCDHUZDPVNJZ-UHFFFAOYSA-N 1-aminocyclohexa-3,5-diene-1,2-dicarbohydrazide Chemical compound NNC(=O)C1C=CC=CC1(N)C(=O)NN IPQCDHUZDPVNJZ-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- ORSQLIPWNOIHJK-UHFFFAOYSA-N 1H-pyrrolo[2,3-g][1]benzazepin-2-one Chemical class C1=CC2=NC=CC=CC2=C2C1=CC(=O)N2 ORSQLIPWNOIHJK-UHFFFAOYSA-N 0.000 description 1
- UAYGFGNTENWCEQ-UHFFFAOYSA-N 1h-imidazo[4,5-b]pyridine-2-carboxamide Chemical class C1=CN=C2NC(C(=O)N)=NC2=C1 UAYGFGNTENWCEQ-UHFFFAOYSA-N 0.000 description 1
- LBYPXCKNONYICH-UHFFFAOYSA-N 2-(3-methoxyphenyl)-1,3-benzoxazole Chemical compound COC1=CC=CC(C=2OC3=CC=CC=C3N=2)=C1 LBYPXCKNONYICH-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- UXGJAOIJSROTTN-UHFFFAOYSA-N 2-[4-(4-chlorophenoxy)phenyl]-3h-benzimidazole-5-carboxamide Chemical compound N1C2=CC(C(=O)N)=CC=C2N=C1C(C=C1)=CC=C1OC1=CC=C(Cl)C=C1 UXGJAOIJSROTTN-UHFFFAOYSA-N 0.000 description 1
- YMZLDAJXSRSNHM-UHFFFAOYSA-N 2-methyl-3,4-dihydroisoquinolin-1-one Chemical compound C1=CC=C2C(=O)N(C)CCC2=C1 YMZLDAJXSRSNHM-UHFFFAOYSA-N 0.000 description 1
- FIISKTXZUZBTRC-UHFFFAOYSA-N 2-phenyl-1,3-benzoxazole Chemical compound C1=CC=CC=C1C1=NC2=CC=CC=C2O1 FIISKTXZUZBTRC-UHFFFAOYSA-N 0.000 description 1
- KLLLJCACIRKBDT-UHFFFAOYSA-N 2-phenyl-1H-indole Chemical class N1C2=CC=CC=C2C=C1C1=CC=CC=C1 KLLLJCACIRKBDT-UHFFFAOYSA-N 0.000 description 1
- DWYHDSLIWMUSOO-UHFFFAOYSA-N 2-phenyl-1h-benzimidazole Chemical compound C1=CC=CC=C1C1=NC2=CC=CC=C2N1 DWYHDSLIWMUSOO-UHFFFAOYSA-N 0.000 description 1
- YWPMKTWUFVOFPL-UHFFFAOYSA-N 3,4-dihydro-2h-isoquinolin-1-one Chemical class C1=CC=C2C(=O)NCCC2=C1 YWPMKTWUFVOFPL-UHFFFAOYSA-N 0.000 description 1
- RLLZPXDJYADIEU-UHFFFAOYSA-N 3,4-dihydro-5-methylisoquinolinone Chemical compound O=C1NCCC2=C1C=CC=C2C RLLZPXDJYADIEU-UHFFFAOYSA-N 0.000 description 1
- GSCPDZHWVNUUFI-UHFFFAOYSA-N 3-aminobenzamide Chemical compound NC(=O)C1=CC=CC(N)=C1 GSCPDZHWVNUUFI-UHFFFAOYSA-N 0.000 description 1
- NGMMGKYJUWYIIG-UHFFFAOYSA-N 3-hydroxybenzamide Chemical compound NC(=O)C1=CC=CC(O)=C1 NGMMGKYJUWYIIG-UHFFFAOYSA-N 0.000 description 1
- VKPLPDIMEREJJF-UHFFFAOYSA-N 3-methoxybenzamide Chemical compound COC1=CC=CC(C(N)=O)=C1 VKPLPDIMEREJJF-UHFFFAOYSA-N 0.000 description 1
- OZUBORKYZRYLSQ-UHFFFAOYSA-N 3-nitrosobenzamide Chemical compound NC(=O)C1=CC=CC(N=O)=C1 OZUBORKYZRYLSQ-UHFFFAOYSA-N 0.000 description 1
- AFTYQAYWAWCYQI-UHFFFAOYSA-N 3-oxothieno[2,3-c]isoquinolin-9-amine Chemical compound N1=C2S(=O)C=CC2=C2C(N)=CC=CC2=C1 AFTYQAYWAWCYQI-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- QIKYZXDTTPVVAC-UHFFFAOYSA-N 4-Aminobenzamide Chemical compound NC(=O)C1=CC=C(N)C=C1 QIKYZXDTTPVVAC-UHFFFAOYSA-N 0.000 description 1
- HGEPGGJUGUMFHT-UHFFFAOYSA-N 4-[3-(1,4-diazepan-1-ylcarbonyl)-4-fluorobenzyl]phthalazin-1(2h)-one Chemical compound FC1=CC=C(CC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N1CCCNCC1 HGEPGGJUGUMFHT-UHFFFAOYSA-N 0.000 description 1
- LTZZZXXIKHHTMO-UHFFFAOYSA-N 4-[[4-fluoro-3-[4-(4-fluorobenzoyl)piperazine-1-carbonyl]phenyl]methyl]-2H-phthalazin-1-one Chemical compound FC1=C(C=C(CC2=NNC(C3=CC=CC=C23)=O)C=C1)C(=O)N1CCN(CC1)C(C1=CC=C(C=C1)F)=O LTZZZXXIKHHTMO-UHFFFAOYSA-N 0.000 description 1
- SSMIFVHARFVINF-UHFFFAOYSA-N 4-amino-1,8-naphthalimide Chemical compound O=C1NC(=O)C2=CC=CC3=C2C1=CC=C3N SSMIFVHARFVINF-UHFFFAOYSA-N 0.000 description 1
- DMJHWHGTAHHHMU-UHFFFAOYSA-N 4-amino-3-chloro-n-[2-(diethylamino)ethyl]benzamide;hydrochloride Chemical compound Cl.CCN(CC)CCNC(=O)C1=CC=C(N)C(Cl)=C1 DMJHWHGTAHHHMU-UHFFFAOYSA-N 0.000 description 1
- 108020005029 5' Flanking Region Proteins 0.000 description 1
- YEKAKJMJAMJFQR-UHFFFAOYSA-N 5-[(3-carbamoylphenyl)carbamoyloxy]pentyl n-(3-carbamoylphenyl)carbamate Chemical compound NC(=O)C1=CC=CC(NC(=O)OCCCCCOC(=O)NC=2C=C(C=CC=2)C(N)=O)=C1 YEKAKJMJAMJFQR-UHFFFAOYSA-N 0.000 description 1
- SVASVGVAQIVSEZ-UHFFFAOYSA-N 5-amino-2H-isoquinolin-1-one Chemical compound C1=CNC(=O)C2=C1C(N)=CC=C2 SVASVGVAQIVSEZ-UHFFFAOYSA-N 0.000 description 1
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- CMNQIVHHHBBVSC-UHFFFAOYSA-N 5-hydroxy-3,4-dihydro-2h-isoquinolin-1-one Chemical compound O=C1NCCC2=C1C=CC=C2O CMNQIVHHHBBVSC-UHFFFAOYSA-N 0.000 description 1
- BCCUXBGEPLKSEX-UHFFFAOYSA-N 5-methylpyridine-3-carboxamide Chemical compound CC1=CN=CC(C(N)=O)=C1 BCCUXBGEPLKSEX-UHFFFAOYSA-N 0.000 description 1
- WWRAFPGUBABZSD-UHFFFAOYSA-N 6-amino-5-iodochromen-2-one Chemical compound O1C(=O)C=CC2=C(I)C(N)=CC=C21 WWRAFPGUBABZSD-UHFFFAOYSA-N 0.000 description 1
- JWIYKMOFSFOAAZ-UHFFFAOYSA-N 8-oxa-15,16-diazatetracyclo[7.7.1.02,7.013,17]heptadeca-1(16),2,4,6,9,11,13(17)-heptaen-14-one Chemical class C12=CC=CC=C2OC2=CC=CC3=C2C1=NNC3=O JWIYKMOFSFOAAZ-UHFFFAOYSA-N 0.000 description 1
- 102000009062 ADP Ribose Transferases Human genes 0.000 description 1
- 108010049290 ADP Ribose Transferases Proteins 0.000 description 1
- SRNWOUGRCWSEMX-KEOHHSTQSA-N ADP-beta-D-ribose Chemical group C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=CN=C(C=2N=C1)N)OP(O)(=O)OP(O)(=O)OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O SRNWOUGRCWSEMX-KEOHHSTQSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 102000002804 Ataxia Telangiectasia Mutated Proteins Human genes 0.000 description 1
- 108010004586 Ataxia Telangiectasia Mutated Proteins Proteins 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 238000012287 DNA Binding Assay Methods 0.000 description 1
- 230000012746 DNA damage checkpoint Effects 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 102100034490 DNA repair and recombination protein RAD54B Human genes 0.000 description 1
- 102100039116 DNA repair protein RAD50 Human genes 0.000 description 1
- 102100027830 DNA repair protein XRCC2 Human genes 0.000 description 1
- 102100027829 DNA repair protein XRCC3 Human genes 0.000 description 1
- 102100037377 DNA-(apurinic or apyrimidinic site) endonuclease 2 Human genes 0.000 description 1
- NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 description 1
- 101100462870 Drosophila melanogaster Parp gene Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102100028779 Endonuclease 8-like 2 Human genes 0.000 description 1
- 102100028773 Endonuclease 8-like 3 Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010040476 FITC-annexin A5 Proteins 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- 230000037059 G2/M phase arrest Effects 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 108091064358 Holliday junction Proteins 0.000 description 1
- 102000039011 Holliday junction Human genes 0.000 description 1
- 101000927847 Homo sapiens DNA ligase 3 Proteins 0.000 description 1
- 101001132263 Homo sapiens DNA repair and recombination protein RAD54B Proteins 0.000 description 1
- 101000743929 Homo sapiens DNA repair protein RAD50 Proteins 0.000 description 1
- 101000649306 Homo sapiens DNA repair protein XRCC2 Proteins 0.000 description 1
- 101000806823 Homo sapiens DNA-(apurinic or apyrimidinic site) endonuclease 2 Proteins 0.000 description 1
- 101001123823 Homo sapiens Endonuclease 8-like 2 Proteins 0.000 description 1
- 101001123819 Homo sapiens Endonuclease 8-like 3 Proteins 0.000 description 1
- 101000615492 Homo sapiens Methyl-CpG-binding domain protein 4 Proteins 0.000 description 1
- 101001128138 Homo sapiens NACHT, LRR and PYD domains-containing protein 2 Proteins 0.000 description 1
- 101000981336 Homo sapiens Nibrin Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 102100033284 Leucine-rich repeats and immunoglobulin-like domains protein 3 Human genes 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000046961 MRE11 Homologue Human genes 0.000 description 1
- 108700019589 MRE11 Homologue Proteins 0.000 description 1
- 108091027974 Mature messenger RNA Proteins 0.000 description 1
- 102100021290 Methyl-CpG-binding domain protein 4 Human genes 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 101100437875 Mus musculus Brca2 gene Proteins 0.000 description 1
- 101100238610 Mus musculus Msh3 gene Proteins 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 102100031897 NACHT, LRR and PYD domains-containing protein 2 Human genes 0.000 description 1
- 239000005104 Neeliglow 4-amino-1,8-naphthalimide Substances 0.000 description 1
- 101100355599 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) mus-11 gene Proteins 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 101710144590 Poly [ADP-ribose] polymerase 2 Proteins 0.000 description 1
- 102100037664 Poly [ADP-ribose] polymerase tankyrase-1 Human genes 0.000 description 1
- 108091026813 Poly(ADPribose) Proteins 0.000 description 1
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 1
- 101710176890 Protein ADP-ribosyltransferase PARP3 Proteins 0.000 description 1
- 102100034935 Protein mono-ADP-ribosyltransferase PARP3 Human genes 0.000 description 1
- 101710204718 Protein mono-ADP-ribosyltransferase PARP3 Proteins 0.000 description 1
- 101150006234 RAD52 gene Proteins 0.000 description 1
- 102000053062 Rad52 DNA Repair and Recombination Human genes 0.000 description 1
- 108700031762 Rad52 DNA Repair and Recombination Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 101710204410 Scaffold protein Proteins 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 108010017601 Tankyrases Proteins 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- 208000035199 Tetraploidy Diseases 0.000 description 1
- QHNORJFCVHUPNH-UHFFFAOYSA-L To-Pro-3 Chemical compound [I-].[I-].S1C2=CC=CC=C2[N+](C)=C1C=CC=C1C2=CC=CC=C2N(CCC[N+](C)(C)C)C=C1 QHNORJFCVHUPNH-UHFFFAOYSA-L 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 108010074310 X-ray repair cross complementing protein 3 Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- NWDCGICEHJVOPW-UHFFFAOYSA-N acetic acid;prop-2-enamide Chemical compound CC(O)=O.NC(=O)C=C NWDCGICEHJVOPW-UHFFFAOYSA-N 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 101150059062 apln gene Proteins 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 208000034615 apoptosis-related disease Diseases 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- QVZZPLDJERFENQ-NKTUOASPSA-N bassianolide Chemical compound CC(C)C[C@@H]1N(C)C(=O)[C@@H](C(C)C)OC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C(C)C)OC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C(C)C)OC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C(C)C)OC1=O QVZZPLDJERFENQ-NKTUOASPSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- IQXIUTMSTALSFW-VJFOLWCZSA-N carboplatin paclitaxel Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1.O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 IQXIUTMSTALSFW-VJFOLWCZSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000012820 cell cycle checkpoint Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 208000013557 cerebral hemisphere cancer Diseases 0.000 description 1
- 201000008860 cerebrum cancer Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- ROGONMNKPBBCET-UHFFFAOYSA-N chembl63211 Chemical compound N=1C(C2=3)=CC=CC=3C(=O)NCCN2C=1C1=CC=CC=C1 ROGONMNKPBBCET-UHFFFAOYSA-N 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000009668 clonal growth Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000012361 double-strand break repair Effects 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N doxorubicine Natural products O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- ZONYXWQDUYMKFB-UHFFFAOYSA-N flavanone Chemical compound O1C2=CC=CC=C2C(=O)CC1C1=CC=CC=C1 ZONYXWQDUYMKFB-UHFFFAOYSA-N 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 239000001046 green dye Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- LFUJIPVWTMGYDG-UHFFFAOYSA-N isoquinoline-1,5-diol Chemical compound N1=CC=C2C(O)=CC=CC2=C1O LFUJIPVWTMGYDG-UHFFFAOYSA-N 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 101150071637 mre11 gene Proteins 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940046159 pegylated liposomal doxorubicin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 125000001151 peptidyl group Chemical group 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000013615 primer Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- ISZIQZCZKOFSBT-UHFFFAOYSA-N pyrrolo[2,3-g][1]benzazepine Chemical class N1=CC=CC=C2C3=NC=CC3=CC=C21 ISZIQZCZKOFSBT-UHFFFAOYSA-N 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- CGJMVNVWQHPASW-UHFFFAOYSA-N quinoxaline-2-carboxamide Chemical class C1=CC=CC2=NC(C(=O)N)=CN=C21 CGJMVNVWQHPASW-UHFFFAOYSA-N 0.000 description 1
- 238000007420 radioactive assay Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000013120 recombinational repair Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 229950009213 rubitecan Drugs 0.000 description 1
- VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 229940079862 sodium lauryl sarcosinate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- ADWNFGORSPBALY-UHFFFAOYSA-M sodium;2-[dodecyl(methyl)amino]acetate Chemical compound [Na+].CCCCCCCCCCCCN(C)CC([O-])=O ADWNFGORSPBALY-UHFFFAOYSA-M 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 230000006354 stress signaling Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- DTYZZRQJAHIKRA-UHFFFAOYSA-N thieno[2,3-c]isoquinoline 3-oxide Chemical class N1=CC2=CC=CC=C2C2=C1S(=O)C=C2 DTYZZRQJAHIKRA-UHFFFAOYSA-N 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- JSPLKZUTYZBBKA-UHFFFAOYSA-N trioxidane Chemical compound OOO JSPLKZUTYZBBKA-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Description
TER006/ 05540
Alla 1
DNA Damage Repair Inhibitors for Treatment of Cancer
This invention relates to the induction of cellular lethality in cancer cells, in particular cancer cells that are deficient in homologous recombination (HR) dependent DNA double strand break (DSB) repair.
The effective repair of DNA damage in cells relies on mechanisms of damage sensing followed by the transduction of damage signals to downstream effectors that arrest at cell cycle checkpoints and repair DNA damage. Cells contain a number of distinct pathways of signals and effectors that mediate the repair of different types of
DNA damage. These pathways include base excision repair (BER), homologous recombination (HR) dependent DNA double strand break (DSB) repair, non-homologous end joining (NHEJ), nucleotide excision repair (NER), base excision repair (BER) and mismatch repair (MMR).
The interaction and interdependence between the various DNA repair pathways remains poorly understood.
The present inventors have discovered that the inhibition of the BER pathway, for example by inhibition of poly (ADP-ribose) polymerase (PARP), is selectively lethal to those cancer cells that are deficient in HR dependent DNA DSB repair pathway. This has important implications in the treatment of cancer conditions.
One aspect of the invention provides the use of an inhibitor of a base excision repair pathway in the manufacture of a medicament for use in the treatment of cancer in an individual, wherein said cancer is deficient in HR dependent DNA DSB repair activity.
A method of treatment of cancer in an individual may comprise; administering an inhibitor of a base excision repairpathway to said individual,
BASS, f rk 0. en : to} _
WO 2005/053662 PCT/GB2004/005025 2 wherein said cancer is deficient in the HR dependent DNA DSB repair pathway.
The cancer may comprise one or more cancer cells having a reduced or abrogated ability to repair DNA by said second repair pathway relative to normal cells.
The HR dependent DNA DSB repair pathway repairs double-strand breaks (DSBs) in DNA via homologous mechanisms to reform a continuous DNA helix (K.K. Khanna and S.P. Jackson, Nat. Genet. 27(3): 247-254 (2001)). The components of the HR dependent DNA DSB repair pathway include ATM (NM_000051) , RAD51 (NM_002875), RADS51L1l (NM_002877),
RADS1C (NM_002876) , RADS51L3 (NM_002878), DMCl1 (NM_007068), XRCC2 (NM_005431), XRCC3 (NM_005432), RAD52 (NM_002879), RADS4L (NM_003579), RAD54B (NM_012415), BRCAl (NM_007295), BRCA2 (NM_000059), RAD50 (NM_005732), MRE11A (NM 005590) and NBS1 oo (NM_002485). Other proteins involved in the HR dependent DNA DSB repair pathway include regulatory factors such as EMSY (Hughes-
Davies et al, Cell, Vol 115, pp523-535).
The base excision repair (BER) pathway repairs DNA single strand breaks and gaps and removes specific damaged bases. Gaps in the DNA helix are filled by the sequential action of a Poly (ADP-Ribose)
Polymerase (PARP) and a ligase. (K.K. Khanna and S.P. Jackson, Nat.
Genet., 27(3): 247-254 (2001); F. Dantzer et al. Biochemistry 39, 7559-69 2000; J. H. Hoeijmakers, Nature 411 366-74 (2001)). An inhibitor of base excision repair may inhibit any one of the components of the base excision repair pathway. Components of the
BER pathway include: UNG (NM_003362), SMUGL (NM 014311), MBD4 (NM_003925), TDG (NM_003211), OGGl (NM_ 002542), MYH (NM_012222),
NTHL1l (NM_002528), MPG (NM_002434), NEIL1l (NM_024608), NEIL2 (NM_145043), NEIL3 (NM_018248), APEl (NM _001641), APE2 (NM 014481),
LIG3 (NM 013975), XRCCl (NM 006297), ADPRT (PARPl) (NM_0016718) and
ADPRTL2 (PARP2) (NP_005475).
~ 0340
Tare JN) > Ug U2
SER006/ C8 S&L
SR NANCE NT
WO 2005/053662 PCT/GB2004/005025 3
BER inhibitors may be used in the treatment of HR dependent DNA DSB repair deficient cancers in combination with a DNA damaging agent.
Preferably, the DNA damaging agent is used in a dosage or formulation that, in the absence of the BER inhibitor, is not lethal to cells. Suitable DNA damaging chemotherapeutic agents are described below.
In some preferred embodiments, an inhibitor of the mammalian enzyme poly (ADP-ribose) polymerase (PARP) (D'Amours et al, (1999) Biochem.
J. 342: 249-268) may be employed. A PARP inhibitor may thus be used for the treatment of a cancer which is deficient in HR dependent DNA
DSB repair. i A method of treatment of a cancer deficient in HR dependent DNA DSB repair in an individual may comprise: ‘administering a PARP inhibitor to said individual.
A PARP inhibitor may be used in the manufacture of a medicament for use in the treatment of cancer in an individual, wherein said cancer is deficient in HR dependent DNA DSB repair.
PARP inhibitors are described in more detail below.
A cancer which is deficient in HR dependent DNA DSB repair may comprise or consist of one or more cancer cells which have a reduced or abrogated ability to repair DNA DSBs through that pathway, relative to normal cells i.e. the activity of the HR dependent DNA
DSB repair pathway may be reduced or abolished in the one or more cancer cells.
The activity of one or more components of the HR dependent DNA DSB repair pathway may be abolished in the one or more cancer cells of an individual having a cancer which is deficient in HR dependent DNA
DSB repair. Components of the HR dependent DNA DSB repair pathway are well characterised in the art (see for example, Wood et al
(2001) Science 291 1284-1289) and include the components listed above,
In some preferred embodiments, the cancer cells may have a BRCAl and/or a BRCA2 deficient phenotype i.e. BRCAl and/or BRCA2 activity is reduced or abolished in the cancer cells. Cancer cells with this phenotype may be deficient in BRCAl and/or BRCA2 i.e. expression and/or activity of BRCA1 and/or BRCA2 may be reduced or abolished in the cancer cells, for example by means of mutation or polymorphism in the encoding nucleic acid, or by means of mutation or polymorphism in a gene encoding a regulatory factor, for example the
EMSY gene which encodes a BRCA2 regulatory factor (Hughes-Davies et al, Cell, Vol 115, pp523-535).
BRCAl and BRCA2 are known tumour suppressors whose wild-type alleles are frequently lost in tumours of heterozygous carriers (Jasin M.
Oncogene. 2002 Dec 16;21(58):8981-93; Tutt et al Trends Mol Med. (2002)8(12):571-6). The association of BRCAl and/or BRCAZ2 mutations with breast cancer is well-characterised in the art (Radice P J Exp
Clin Cancer Res. 2002 Sep;21(3 Suppl):9-12). Amplification of the
EMSY gene, which encodes a BRCA2 binding factor, is also known to be associated with breast and ovarian cancer.
Carriers of mutations in BRCAl and/or BRCA2 are also at elevated risk of cancer of the ovary, prostate and pancreas.
In some embodiments, a cancer condition in an individual may have been previously identified as a cancer which is deficient in HR dependent DNA DSB repair.
In other embodiments, a method as described herein may comprise the step of identifying a cancer condition in an individual as deficient in HR dependent DNA DSB repair.
A cancer may be identified as a HR dependent DNA DSB repair deficient cancer, for example, by determining the activity of the HR dependent DNA DSB repair pathway in one or more cancer cells from a sample obtained from the individual or by determining the activity of one or more components of the pathway. Activity may be determined relative to normal (i.e. non-cancer) cells, preferably from the same tissue.
The activity of the HR dependent DNA DSB repair pathway may be determined by measuring the formation of foci containing Rad51 in the nucleus in response to DNA damaging agents or PARP inhibitors.
Cells deficient in the HR dependent DNA DSB repair pathway lack the ability to produce such foci. The presence of Rad51 foci may be determined using standard immunofluorescent techniques.
Other methods for determining the activity of the HR dependent DNA
DSB repair pathway may include sensitivity to IR, chemotherapeutics : . oo such as inter-strand cross linking reagents, DSB inducing agents (Topoisomerase I & II inhibitors) as well as the use of western blot analysis, immunohistology, chromosomal abnormalities, enzymatic or
DNA binding assays and plasmid-based assays.
In some embodiments, a cancer may be identified as deficient in an
HR dependent DNA DSB repair pathway by determining the presence in cancer cells from the individual of one or more variations, for example, polymorphisms or mutations, in a nucleic acid encoding a polypeptide which is a component of the HR dependent DNA DSB repair pathway.
Sequence variations such as mutations and polymorphisms may include a deletion, insertion or substitution of one or more nucleotides, relative to the wild-type nucleotide sequence. In some embodiments, the variation may be a gene amplication, for example an amplification of the EMSY gene (CAD22881l; gene symbol CLl1ORF30). The one or more variations may be in a coding or non-coding region of the nucleic acid sequence and, may reduce or abolish the expression or function of the HR dependent DNA DSB repair pathway component polypeptide. In other words, the variant nucleic acid may encode a variant polypeptide which has reduced or abolished activity or may encode a wild-type polypeptide which has little or no expression within the cell, for example through the altered activity of a regulatory element. A variant nucleic acid may have one, two, three, four or more mutations or polymorphisms relative to the wild-type sequence.
The presence of one or more variations in a nucleic acid which encodes a component of the HR dependent DNA DSB repair pathway, may be determined by detecting, in one or more cells of a test sample, the presence of an encoding nucleic acid sequence which comprises the one or more mutations or polymorphisms, or by detecting the presence of the variant component polypeptide which is encoded by
SL the nucleic acid sequence. .
Various methods are available for determining the presence or absence in a sample obtained from an individual of a particular nucleic acid sequence, for example a nucleic acid sequence which has a mutation or polymorphism that reduces or abrogates the expression or activity of a HR dependent DNA DSB repair pathway component.
Furthermore, having sequenced nucleic acid of an individual or sample, the sequence information can be retained and subsequently searched without recourse to the original nucleic acid itself.
Thus, for example, scanning a database of sequence information using sequence analysis software may identify a sequence alteration or mutation.
Methods according to some aspects of the present invention may comprise determining the binding of an oligonucleotide probe to nucleic acid obtained from the sample, for example, genomic DNA, RNA or cDNA. The probe may comprise a nucleotide sequence which binds specifically to a nucleic acid sequence which contains one or more mutations or polymorphisms and does not bind specifically to the nucleic acid sequence which does not contain the one or more mutations or polymorphisms, or vice versa.
The oligonucleotide probe may comprise a label and binding of the probe may be determined by detecting the presence of the label.
A method may include hybridisation of one ox more (e.g. two) oligonucleotide probes or primers to target nucleic acid. Where the nucleic acid is double-stranded DNA, hybridisation will generally be preceded by denaturation to produce single-stranded DNA. The hybridisation may be as part of a PCR procedure, or as part of a probing procedure not involving PCR. An example procedure would be a combination of PCR and low stringency hybridisation.
Binding of a probe to target nucleic acid (e.g. DNA) may be measured using any of a variety of techniques at the disposal of those i skilled in the art. For instance, probes may be radioactively, fluorescently or enzymatically labelled. Other methods not employing labelling of probe include examination of restriction fragment length polymorphisms, amplification using PCR, RN'ase cleavage and allele specific oligonucleotide probing. Probing may employ the standard Southern blotting technique. For instance, DNA may be extracted from cells and digested with different restriction enzymes. Restriction fragments may then be separated by electrophoresis on an agarose gel, before denaturation and transfer to a nitrocellulose filter. Labelled probe may be hybridised to the
DNA fragments on the filter and binding determined.
Those skilled in the art are well able to employ suitable conditions of the desired stringency for selective hybridisation, taking into account factors such as oligonucleotide length and base composition, temperature and so on.
Suitable selective hybridisation conditions for oligonucleotides of 17 to 30 bases include hybridization overnight at 42°C in 6X SSC and washing in 6X SSC at a series of increasing temperatures from 42°C to 65°C.
Other suitable conditions and protocols are described in Molecular
Cloning: a Laboratory Manual: 3rd edition, Sambrook & Russell (2001)
Cold Spring Harbor Laboratory Press NY and Current Protocols in
Molecular Biology, Ausubel et al. eds. John Wiley & Sons (1992).
Nucleic acid, which may be genomic DNA, RNA or cDNA, or an amplified region thereof, may be sequenced to identify or determine the presence of polymorphism or mutation therein. A polymorphism or mutation may be identified by comparing the sequence obtained with the database sequence of the component, as set out above. In particular, the presence of one or more polymorphisms or mutations that cause abrogation or loss of function of the polypeptide component, and thus the HR dependent DNA DSB repair pathway as a whole, may be determined.
Sequencing may be performed using any one of a range of standard techniques. Sequencing of an amplified product may, for example, involve precipitation with isopropanol, resuspension and sequencing using a TaqFS+ Dye terminator sequencing kit. Extension products may be electrophoresed on an ABI 377 DNA sequencer and data analysed using Sequence Navigator software.
A specific amplification reaction such as PCR using one or more pairs of primers may conveniently be employed to amplify the region of interest within the nucleic acid sequence, for example, the portion of the sequence suspected of containing mutations or polymorphisms. The amplified nucleic acid may then be sequenced as above, and/or tested in any other way to determine the presence or absence of a mutation or polymorphism which reduces or abrogates the expression or activity of the HR dependent DNA DSB repair pathway component.
S
Suitable amplification reactions include the polymerase chain reaction (PCR) (reviewed for instance in "PCR protocols; A Guide to i
Methods and Applications", Eds. Innis et al, 1990, Academic Press,
New York, Mullis et al, Cold Spring Harbor Symp. Quant. Biol., 51:263, (1987), Ehrlich (ed), PCR technology, Stockton Press, NY, 1989, and Ehrlich et al, Science, 252:1643-1650, (1991)).
In some embodiments, a cancer may be identified as deficient in a HR dependent DNA DSB repair by assessing the level of expression or activity of a positive or negative regulator of a component of the
HR dependent DNA DSB repair pathway, such as EMSY. Expression levels may be determined, for example, by Western blot, ELISA, RT-
PCR, nucleic acid hybridisation or karyotypic analysis.
In some preferred embodiments, the individual is heterozygous for oo one or more variations, such as mutations and polymorphisms, in
BRCAl and/or BRCA2 or a regulator thereof. The detection of variation in BRCAl and BRCA2 is well-known in the art and is described, for example in EP699754, EP705903, Neuhausen S.L. and
Ostrander E.A. Genet. Test (1992) 1, 75-83; Chappnis, P.O. and
Foulkes, W.D. Cancer Treat Res (2002) 107, 29-59; Janatova M et al
Neoplasma. 2003: 50(4):246-50; Jancarkova N Ceska Gynekol. 2003 68(1): 11-6). Determination of amplification of the BRCAZ binding factor EMSY is described in Hughes-Davies et al Cell 115 523-535).
Mutations and polymorphisms associated with cancer may also be detected at the protein level by detecting the presence of a variant (i.e. a mutant or allelic variant) polypeptide.
A method of identifying a cancer cell in a sample from an individual as deficient in HR dependent DNA DSB repair may include contacting a sample with a specific binding member directed against a variant (e.g. a mutant) polypeptide component of the pathway, and determining binding of the specific binding member to the sample.
Binding of the specific binding member to the sample may be indicative of the presence of the variant polypeptide component of the HR dependent DNA DSB repair pathway in a cell within the sample.
Preferred specific binding molecules for use in aspects of the present invention include antibodies and fragments or derivatives thereof (‘antibody molecules’). . The reactivities of a binding member such as an antibody on normal and test samples may be determined by any appropriate means.
Tagging with individual reporter molecules is one possibility. The reporter molecules may directly or indirectly generate detectable, and preferably measurable, signals. The linkage of reporter molecules may be directly or indirectly, covalently, e.g. via a peptide bond or non-covalently. Linkage via a peptide bond may be as a result of recombinant expression of a gene fusion encoding binding molecule (e.g. antibody) and reporter molecule. oo
The mode of determining binding is not a feature of the present invention and those skilled in the art are able to choose a suitable mode according to their preference and general knowledge.
Cancer cells in general are characterised by abnormal proliferation relative to normal cells and typically form clusters or tumours in an individual having a cancer condition.
A cancer condition which is deficient in the HR dependent DNA DSB repair pathway as described herein may include any type of solid cancer or malignant lymphoma and especially leukaemia, sarcomas, skin cancer, bladder cancer, breast cancer, uterus cancer, ovary cancer, prostate cancer, lung cancer, colorectal cancer, cervical cancer, liver cancer, head and neck cancer, oesophageal cancer, pancreas cancer, renal cancer, stomach cancer and cerebral cancer.
In some preferred embodiments, the cancer condition may be breast, ovary, pancreas or prostate cancer. Cancers may be familial or sporadic,
A sample obtained from an individual may be a tissue sample comprising one or more cells, for example a biopsy from a cancerous tissue as described above, or a non-cancerous tissue, for example for use as a control.
Methods of the invention may be useful in assessing an individual having a cancer condition, for example in order to determine a therapeutic course of action. A method of assessing an individual having a cancer condition may comprise; identifying a cancer cell obtained from the individual as deficient in HR dependent DNA DSB repair relative to normal cells, and; providing a inhibitor of the BER pathway suitable for administration to said individual.
In some preferred embodiments, the BER pathway inhibitor is a PARP inhibitor. PARP inhibitors are described in more detail below. A : method of assessing a cancer condition may comprise; identifying a cancer cell obtained from the individual as deficient in HR dependent DNA DSB repair relative to normal cells, and; providing a PARP inhibitor suitable for administration to said individual.
In some preferred embodiments, the cancer cell which is identified as deficient in HR dependent DNA DSB repair may have a BRCAl or
BRCA2 deficient phenotype.
An individual may have a predisposition to a cancer which is deficient in HR dependent DNA DSB repair. Methods and means of the invention are particularly useful for such individuals.
An individual may, for example, be heterozygous for a mutation or polymorphism in a nucleic acid encoding a component of the HR dependent DNA DSB repair pathway, for example a nucleic acid encoding a component described above.
A method of treatment of cancer in an individual may comprise; administering a BER pathway inhibitor to said individual, wherein .said individual is heterozygous for a mutation or polymorphism in a gene encoding a component of the HR dependent DNA
DSB repair pathway.
A BER inhibitor may be used in the manufacture of a medicament for use in the treatment of a cancer in an individual who is heterozygous for a mutation in a gene of a HR dependent DNA DSB repair pathway and a base excision repair inhibitor may be used in . the treatment of a cancer in an individual who is heterozygous for a mutation in a gene which encodes a component of the HR dependent DNA
L . DSB repair pathway }
In some preferred embodiments, an individual who is heterozygous for a mutation or polymorphism in a gene which encodes a component of the HR dependent DNA DSB repair pathway may be heterozygous for a mutation or polymorphism in BRCAl and/or BRCA2.
A BER inhibitor suitable for use in a method described herein may be any compound or entity, such as a small organic molecule, peptide or nucleic acid, which inhibits, reduces or abolishes the activity of one or more components of the BER pathway.
In some preferred embodiments, the BER inhibitor may reduce or abolish the activity of the enzyme poly (ADP-ribose) polymerase (PARP) .
The term PARP as used herein refers to PARPl (EC 2.4.2.30, Genbank
No: M32721) and/or PARP2 (Ame et al J. Biol. Chem. (1999) 274 15504- 15511; Genbank No: AJ236912) unless context dictates otherwise.
Examples of compounds which are known PARP inhibitors and which may be used in accordance with the invention include: 1. Nicotinamides, such as 5-methyl nicotinamide and O- (2-hydroxy- 3-piperidino-propyl)-3-carboxylic acid amidoxime, and analogues and derivatives thereof. 2. Benzamides, including 3-substituted benzamides such as 3- aminobenzamide, 3-hydroxybenzamide, 3-nitrosobenzamide, 3- methoxybenzamide and 3-chloroprocainamide, and 4-aminobenzamide, 1, 5-di[(3-carbamoylphenyl)aminocarbonyloxy] pentane, and analogues and derivatives thereof. 3. Isoquinolinones and Dihydroisoquinolinones, including 2H- isoquinclin-l-ones, 3H-quinazolin-4-ones, 5-substituted dihydroisoquinolinones such as 5-hydroxy dihydroisoquinolinone, 5-
methyl dihydroisoquinolinone, and 5-hydroxy isoquinolinone, 5-amino isoquinolin-l-one, 5-dihydroxyisoquinolinone, 3, 4 dihydroisoquinolin-1(2H)-ones such as 3, 4 dihydro-5-methoxy- isoquinolin-1(2H)~one and 3, 4 dihydro-5-methyl-1(2H)isoquinolinone, isoquinolin-1(2H)-ones, 4,5-dihydro-imidazo[4,5,1-ijlquinolin-6- ones, 1, 6,-naphthyridine-5(6H)-ones, 1,8-naphthalimides such as 4- amino-1,8-naphthalimide, isoquinolinone, 3, 4-dihydro-5-[4-1{(1- piperidinyl) butoxy]-1(2H)-isoquinolinone, 2, 3- dihydrobenzo[de] isoquinolin-l-one, l-1llb-dihydro-{2H]benzopyrano(4, 3, 2-de]isoquinolin-3-one, and tetracyclic lactams, including benzpyranoisoquinolinones such as benzopyrano(4, 3, 2-de] isoquinolinone, and analogues and derivatives thereof 4. Benzimidazoles and indoles, including benzoxazole-4- carboxamides, benzimidazole-4-carboxamides, such as 2-substituted benzoxazole 4-carboxamides and 2-substituted benzimidazole 4- carboxamides such as 2-aryl benzimidazole 4-carboxamides and 2- cycloalkylbenzimidazole-4-carboxamides including 2-(4-hydroxphenyl) benzimidazole 4-carboxamide, quinoxalinecarboxamides,
imidazopyridinecarboxamides, 2-phenylindoles, 2-substituted benzoxazoles, such as 2-phenyl benzoxazole and 2-(3-methoxyphenyl) benzoxazole, 2-substituted benzimidazoles, such as 2-phenyl benzimidazole and 2-(3-methoxyphenyl) benzimidazole, 1, 3, 4, 5 tetrahydro-azepino{5, 4, 3-cd]indol-6-one, azepinoindoles and azepinoindolones such as 1, 5 dihydro-azepino{4, 5, 6-cd]indolin-6- one and dihydrodiazapinoindolinone, 3-substituted dihydrodiazapinoindolinones, such as 3-(4-trifluoromethylphenyl)- dihydrodiazapinoindolinone, tetrahydrodiazapinoindolinone and 5,6, - dihydroimidazo[4, 5, 1-j, k](1l, 4]benzodiazopin-7(4H)-one, 2-phenyl- 5,6-dihydro-imidazo[4,5,1-jk] [1,4]benzodiazepin-7 (4H) -one and 2, 3, dihydro-isoindol-l-one, and analogues and derivatives thereof 5. Phthalazin-1(2H)-ones and quinazolinones, such as 4- hydroxyquinazoline, phthalazinone, 5-methoxy-4-methyl-1(2) phthalazinones, 4-substituted phthalazinones, 4-(l-piperazinyl)- } 1(2H)-phthalazinone, tetracyclic benzopyrano [4, 3, 2-de] phthalazinones and tetracyclic indeno [1l, 2, 3-de] phthalazinones and 2-substituted quinazolines, such as 8-hydroxy-2- methylquinazolin-4- (3H) one, tricyclic phthalazinones and 2- aminophthalhydrazide, and analogues and derivatives thereof. 6. Isoindolinones and analogues and derivatives thereof 7. Phenanthridines and phenanthridinones, such as 5[H]phenanthridin- 6-one, substituted 5[H] phenanthridin-6-ones, especially 2-, 3- substituted 5[H] phenanthridin-6-ones and sulfonamide/carbamide derivatives of 6(5H)phenanthridinones, thieno[2, 3-c]isoquinolones such as 9-amino thieno[2, 3-c]isoquinolone and 9-hydroxythieno(2, 3- c]lisoquinolone, 9-methoxythieno[2, 3-c]isoquinolone, and N-(6-oxo-5, 6-dihydrophenanthridin-2-yl]-2-(N,N~-dimethylamino}acetamide, substituted 4,9-dihydrocyclopenta(lmn]phenanthridine-5-ones, and analogues and derivatives thereof.
8. Benzopyrones such as 1, 2-benzopyrone, 6-nitrosobenzopyrone, 6- nitroso 1, 2-benzopyrone, and 5-iodo-6-aminobenzopyrone, and analogues and derivatives thereof. 9. Unsaturated hydroximic acid derivatives such as 0-(3- piperidino-2-hydroxy-1l-propyl)nicotinic amidoxime, and analogues and derivatives thereof. 10. Pyridazines, including fused pyridazines and analogues and derivatives thereof. 11. Other compounds such as caffeine, theophylline, and thymidine, and analogues and derivatives thereof.
Additional PARP inhibitors are described for example in US6,635,642,
Us85,587,384, W02003080581, W02003070707, W02003055865, W02003057145,
W02003051879, US6514983, W02003007959, US6426415, wW02003007958,
W020020384790, W02002068407, US6476048, W02001090077, wW02001085687,
WO02001085686, WO2001079184, W02001057038, W02001023390,
W02001021615, WO02001016136, W02001012199, W09524379, Banasik et al.
J. Biol. Chem., 267:3, 1569-75 (1992), Banasik et al. Molec. Cell.
Biochem. 138:185-97 (1994)), Cosi (2002) Expert Opin. Ther. Patents 12 (7), and Southan & Szabo (2003) Curr Med Chem 10 321-340 and references therein.
One preferred class of suitable PARP inhibitors includes phthalazinones such as 1(2H)-phthalazinone and derivatives thereof, as described in W002/36576. In particular, compounds of the formula: 0
A or ~N
B
Re and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, may be used for inhibiting PARP, wherein:
A and B together represent an optionally substituted, fused aromatic ring;
Rc is represented by -L-R;, where L is of formula: = (CHz) n1~Qn2— (CH2) n3~ wherein n;, n, and nj; are each selected from 0, 1, 2 and 3, the sum of m, n; and n; is 1, 2 or 3 and Q is selected from 0, S, NH, C(=0) . or -CR;R;-, where R; and R, are independently selected from hydrogen, halogen or optionally substituted C;., alkyl, or may together with the carbon atom to which they are attached form a Ci, cyclic alkyl group, which may be saturated (a Cs; cycloalkyl group) or unsaturated (a C3; cycloalkenyl group), or one of R; and R; may be attached to an atom in Ry to form an unsaturated C;.; cycloalkenyl group which comprises the carbon atoms to which R, and R; are attached in Q, -(CH;).3- (if present) and part of Ry; and R, is optionally substituted Cs-50 aryl; and
Ry is selected from hydrogen, optionally substituted C;.; alkyl, Ci heterocyclyl, and Cs; aryl, hydroxy, ether, nitro, amino, amido, thiol, thioether, sulfoxide and sulfone.
Preferably a compound of the formula: 0 hed
B | oN
Re or an isomer, salt, solvate, chemically protected form, or prodrug thereof may be used to inhibit PARP, wherein:
A and B together represent an optionally substituted, fused aromatic ring;
Re is -CH;-Ry;
R, is optionally substituted phenyl; and
Ry is hydrogen.
In some preferred embodiments, a compound having the structure of
KU-0058684 or KU-0058948 as set out in Figure 2, or an isomer, salt, solvate, chemically protected form, or prodrug thereof, may be used to inhibit PARP.
Suitable PARP inhibitors are either commercially available or may be synthesized by known methods from starting materials that are known (see, for example, Suto et al. Anticancer Drug Des. 6:107-17 (1991).
Another class of base excision repair inhibitors includes peptide fragments of components of the BER pathway. For example, peptide fragments of the PARP sequence may be used to inhibit PARP and thus reduce or abolish activity of the BER pathway. Peptide fragments may be generated wholly or partly by chemical synthesis using the published sequences of the components, for example the published
PARP sequence (Acc No: NM 001618). Peptide fragments can be readily prepared according to well-established, standard liquid or, preferably, solid-phase peptide synthesis methods, general descriptions of which are broadly available (see, for example, in
J.M. Stewart and J.D. Young, Solid Phase Peptide Synthesis, 2nd edition, Pierce Chemical Company, Rockford, Illinois (1984), in M.
Bodanzsky and A. Bodanzsky, The Practice of Peptide Synthesis,
Springer Verlag, New York (1984); and Applied Biosystems 430A Users
Manual, ABI Inc., Foster City, California), or they may be prepared in solution, by the liquid phase method or by any combination of solid-phase, liquid phase and solution chemistry, e.g. by first completing the respective peptide portion and then, if desired and appropriate, after removal of any protecting groups being present, by introduction of the residue X by reaction of the respective carbonic or sulfonic acid or a reactive derivative thereof.
Other candidate compounds for inhibiting a component of the BER pathway, such as PARP, may be based on modelling the 3-dimensional structure of the component and using rational drug design to provide candidate compounds with particular molecular shape, size and charge characteristics. A candidate inhibitor, for example, may be a "functional analogue” of a peptide fragment or other compound which inhibits the component. A functional analogue has the same functional activity as the peptide or other compound in question, i.e. it may interfere with the interactions or activity of the DNA repair pathway component. Examples of such analogues include chemical compounds which are modelled to resemble the three dimensional structure of the component in an area which contacts another component, and in particular the arrangement of the key amino acid residues as they appear.
Another class of suitable BER pathway inhibitors includes nucleic acid encoding part or all of the amino acid sequence of a component of the BER pathway, such as PARP (Acc No: NM_001618), or the complement thereof, which inhibit activity or function by down- regulating production of active polypeptide.
For example, the inhibition of PARP activity may be determined using conventional methods, including for example dot blots (Affar EB et al Anal Biochem. 1998;259(2):280-3), and BER assays that measure the direct activity of PARP to form poly ADP-ribose chains for example by using radioactive assays with tritiated substrate NAD or specific antibodies to the polymer chains formed by PARP activity (K.J.
Dillon et al, Journal of Biomolecular Screening, 8(3): 347-352 (2003).
For instance, expression of a BER pathway component may be inhibited using anti-sense or RNAi technology. The use of these approaches to down-regulate gene expression is now well-established in the art.
Anti-sense oligonucleotides may be designed to hybridise to the complementary sequence of nucleic acid, pre-mRNA or mature mRNA,
interfering with the production of the base excision repair pathway component so that its expression is reduced or completely or substantially completely prevented. In addition to targeting coding sequence, anti-sense techniques may be used to target control sequences of a gene, e.g. in the 5' flanking sequence, whereby the anti-sense oligonucleotides can interfere with expression control sequences. The construction of anti-sense sequences and their use is described for example in Peyman and Ulman, Chemical Reviews, 90:543-584, (1990) and Crooke, Ann. Rev. Pharmacol. Toxicol. 32:329- 376, (1992).
Oligonucleotides may be generated in vitro or ex vivo for administration or anti-sense RNA may be generated in vivo within cells in which down-regulation is desired. Thus, double-stranded DNA may be placed under the control of a promoter in a "reverse orientation” such that transcription of the anti-sense strand of the
DNA yields RNA which is complementary to normal mRNA transcribed from the sense strand of the target gene. The complementary anti- sense RNA sequence is thought then to bind with mRNA to form a duplex, inhibiting translation of the endogenous mRNA from the target gene into protein. Whether or not this is the actual mode of action is still uncertain. However, it is established fact that the technique works. . The complete sequence corresponding to the coding sequence in reverse orientation need not be used. For example fragments of sufficient length may be used. It is a routine matter for the person skilled in the art to screen fragments of various sizes and from various parts of the coding or flanking sequences of a gene to optimise the level of anti~sense inhibition. It may be advantageous to include the initiating methionine ATG codon, and perhaps one or more nucleotides upstream of the initiating codon. A suitable fragment may have about 14-23 nucleotides, e.g. about 15, 16 or 17.
An alternative to anti-sense is to use a copy of all or part of the target gene inserted in sense, that is the same, orientation as the target gene, to achieve reduction in expression of the target gene by co-suppression; Angell & Baulcombe (1997) The EMBO Journal 16,12:3675-3684; and Voinnet & Baulcombe (1997) Nature 389: pg 553).
Double stranded RNA (dsRNA) has been found to be even more effective in gene silencing than both sense or antisense strands alone (Fire
A. et al Nature 391, (1998)). dsRNA mediated silencing is gene specific and is often termed RNA interference (RNAi).
RNA interference is a two-step process. First, dsRNA is cleaved within the cell to yield short interfering RNAs (siRNAs) of about 21-23nt length with 5' terminal phosphate and 3' short overhangs (~2nt). The siRNAs target the corresponding mRNA sequence specifically for destruction (Zamore P.D. Nature Structural Biology, 8, 9, 746-750, (2001)
RNAi may also be efficiently induced using chemically synthesized siRNA duplexes of the same structure with 3'-overhang ends (Zamore
PD et al Cell, 101, 25-33, (2000)). Synthetic siRNA duplexes have been shown to specifically suppress expression of endogenous and heterologeous genes in a wide range of mammalian cell lines (Elbashir SM. et al. Nature, 411, 494-498, (2001)).
Another possibility is that nucleic acid is used which on transcription produces a ribozyme, able to cut nucleic acid at a specific site - thus also useful in influencing gene expression.
Background references for ribozymes include Kashani-Sabet and
Scanlon, 1995, Cancer Gene Therapy, 2{3): 213-223, and Mercola and
Cohen, 1995, Cancer Gene Therapy, 2(1), 47-59.
Methods of the invention may comprise administering a BER inhibitor, such as a PARP inhibitor, to an individual. This may occur subsequent to having identified the individual as having a cancer condition deficient in HR dependent DNA DSB repair.
While it is possible for the active compound to be administered alone, it is preferable to present it as a pharmaceutical composition (e.g., formulation) comprising at least one active compound, as defined above, together with one or more pharmaceutically acceptable carriers, adjuvants, excipients, diluents, fillers, buffers, stabilisers, preservatives, lubricants, or other materials well known to those skilled in the art and optionally other therapeutic or prophylactic agents.
Pharmaceutical compositions comprising Base excision repair inhibitors as defined above, for example an inhibitor admixed together with one or more pharmaceutically acceptable carriers, excipients, buffers, adjuvants, stabilisers, or other materials, as described herein, may be used in the methods described herein.
The term “pharmaceutically acceptable” as used herein pertains to compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgement, suitable for use in contact with the tissues of a subject (e.g., human) without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
Each carrier, excipient, etc. must also be “acceptable” in the sense of being compatible with the other ingredients of the formulation.
Suitable carriers, excipients, etc. can be found in standard pharmaceutical texts, for example, Remington’s Pharmaceutical
Sciences, 18th edition, Mack Publishing Company, Easton, Pa., 1990.
The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. Such methods include the step of bringing the active compound into association with a carrier which may constitute one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the active compound with liquid carriers or finely divided solid carriers or both, and then if necessary shaping the product.
Formulations may be in the form of liquids, solutions, suspensions, emulsions, elixirs, syrups, tablets, lozenges, granules, powders, capsules, cachets, pills, ampoules, suppositories, pessaries, ointments, gels, pastes, creams, sprays, mists, foams, lotions, olls, boluses, electuaries, or aerosols.
The BER inhibitor or pharmaceutical composition comprising the inhibitor may be administered to a subject by any convenient route of administration, whether systemically/ peripherally or at the site of desired action, including but not limited to, oral (e.g. by ingestion); topical (including e.g. transdermal, intranasal, ocular, buccal, and sublingual); pulmonary (e.g. by inhalation or insufflation therapy using, e.g. an aerosol, e.g. through mouth or nose); rectal; vaginal; parenteral, for example, by injection, including subcutaneous, intradermal, intramuscular, intravenous, intraarterial, intracardiac, intrathecal, intraspinal, intracapsular, subcapsular, intraorbital, intraperitoneal, intratracheal, subcuticular, intraarticular, subarachnoid, and intrasternal; by implant of a depot, for example, subcutaneously or intramuscularly.
Formulations suitable for oral administration (e.g., by ingestion) may be presented as discrete units such as capsules, cachets or - tablets, each containing a predetermined amount of the active compound; as a powder or granules; as a solution or suspension in an aqueous or non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion; as a bolus; as an electuary; or as a paste.
A tablet may be made by conventional means, e.g., compression or molding, optionally with one or more accessory ingredients.
Compressed tablets may be prepared by compressing in a suitable machine the active compound in a free-flowing form such as a powder or granules, opticnally mixed with one or more binders (e.g., povidone, gelatin, acacia, sorbitol, tragacanth, hydroxypropylmethyl cellulose); fillers or diluents (e.g., lactose, microcrystalline cellulose, calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc, silica); disintegrants (e.g., sodium starch glycolate, cross-linked povidone, cross-linked sodium carboxymethyl cellulese); surface-active or dispersing or wetting agents (e.g., sodium lauryl sulfate); and preservatives (e.g., methyl p-hydroxybenzoate, propyl p-hydroxybenzoate, sorbic acid). Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active compound therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile. Tablets may optionally be provided with an enteric coating, to provide release in parts of the gut other than the stomach.
Formulations suitable for parenteral administration (e.g., by injection, including cutaneous, subcutaneous, intramuscular, intravenous and intradermal), include aqueous and non-aqueous isotonic, pyrogen-free, sterile injection solutions which may contain anti-oxidants, buffers, preservatives, stabilisers, bacteriostats, and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non- aqueous sterile suspensions which may include suspending agents and thickening agents, and liposomes or other microparticulate systems which are designed to target the compound to blood components or one or more organs. Examples of suitable isotonic vehicles for use in such formulations include Sodium Chloride Injection, Ringer=s
Solution, or Lactated Ringer's Injection. Typically, the concentration of the active compound in the solution is from about 1 ng/ml to about 10 pg/ml, for example from about 10 ng/ml to about 1 pg/ml. The formulations may be presented in unit-dose or multi- dose sealed containers, for example, ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules, and tablets. Formulations may be in the form of liposomes or other microparticulate systems which are designed to target the active compound to blood components or one or mcre organs.
It will be appreciated that appropriate dosages of the active compounds, and compositions comprising the active compounds, can vary from patient to patient. Determining the optimal dosage will generally involve the balancing of the level of therapeutic benefit against any risk or deleterious side effects of the treatments of the present invention. The selected dosage level will depend on a variety of factors including, but not limited to, the activity of the particular compound, the route of administration, the time of : administration, the rate of excretion of the compound, the duration of the treatment, other drugs, compounds, and/or materials used in combination, and the age, sex, weight, condition, general health, and prior medical history of the patient. The amount of compound and route of administration will ultimately be at the discretion of the physician, although generally the dosage will be to achieve local concentrations at the site of action which achieve the desired effect without causing substantial harmful or deleterious side- effects.
Compositions comprising BER pathway inhibitors may be used in the methods described herein in combination with standard chemotherapeutic regimes that damage cancer cell DNA. Suitable agents may include inhibitors of topoisomerase I and II activity, such as camptothecin, drugs such as irinotecan, topotecan and rubitecan, alkylating agents such as temozolomide and DTIC (dacarbazine), and platinum agents like cisplatin, cisplatin- doxorubicin~cyclophosphamide, carboplatin, and carboplatin- paclitaxel.
Other suitable chemotherapeutic agents include doxorubicin- cyclophosphamide, capecitabine, cyclophosphamide-methotrexate-5- fluorouracil, docetaxel, 5-flouracil-epirubicin-cyclophosphamide, paclitaxel, vinorelbine, etoposide, pegylated liposomal doxorubicin and topotecan.
The treatment of individuals using such agents is well-known in the art.
Administration in vivo can be effected in one dose, continuously or intermittently (e.g., in divided doses at appropriate intervals) throughout the course of treatment. Methods of determining the most effective means and dosage of administration are well known to those of skill in the art and will vary with the formulation used for therapy, the purpose of the therapy, the target cell being treated, and the subject being treated. Single or multiple administrations can be carried out with the dose level and pattern being selected by the treating physician.
In general, a suitable dose of the active compound is in the range of about 100 pg to about 250 mg per kilogram body weight of the subject per day. Where the active compound is a salt, an ester, prodrug, or the like, the amount administered is calculated on the basis of the parent compound and so the actual weight to be used is increased proportionately.
Methods of the invention may also be useful in investigating and assessing a cancer condition in an individual.
A method of assessing the activity of the HR dependent DNA DSB repair pathway in a cancer condition may comprise; contacting a base excision repair inhibitor with a sample of cancer cells obtained from the individual having the condition, and: determining the amount of cell death in said sample relative to a control sample.
An increase in cell death in the sample relative to control cells which have normal levels of HR dependent DNA DSB repair activity is indicative that the cancer is deficient in HR dependent DNA DSB repair.
The individual may have a cancer condition and the sample may be a sample of cancer cells, for example from a tumour biopsy.
In preferred embodiments, the base excision repair inhibitor is a
PARP inhibitor. A method of assessing HR dependent DNA DSB repair in a cancer condition may thus comprise; contacting a PARP inhibitor with a sample of cancer cells obtained from the individual having the cancer condition, and; determining the amount of cell death in said sample relative to a control sample.
An increased sensitivity the PARP inhibitor in cells from the sample relative to control cells is indicative that the cancer is deficient in the HR dependent DNA DSB repair activity.
Increased sensitivity to PARP inhibitors may be indicative that the cancer cells have a BRCAl or BRCA2 deficient phenotype, for example a reduction or abolition of BRCAl or BRCA2 expression or activity.
A cancer condition identified as being deficient in HR dependent DNA
DSB repair activity, for example a condition having a BRCAl or BRCA2 deficient phenotype, may be subjected to therapies that are specifically directed at such conditions. Suitable therapies may include the use of DNA cross-linking agents such as Mitomycin C, cisplatin or carboplatin.
Methods may be used to predict the response of a cancer condition in an individual to a treatment targeting HR, for example a treatment specific to cancers having a BRCAl or BRCA2 deficient phenotype.
A method of predicting the response of a cancer condition in an individual to a treatment targeting cancers deficient in HR dependent DNA DSB repair may comprise; contacting a BER inhibitor, for example a PARP inhibitor, with a sample of cancer cells obtained from the individual having the cancer condition, and; determining the amount of cell death in said sample relative to a control sample.
An increase in cell death in the sample relative to control cells which have normal levels of HR dependent DNA DSB repair activity (i.e. an increased sensitivity to PARP inhibitors) is indicative that the cancer may be responsive to said treatment.
Treatments which target cancers deficient in HR dependent DNA DSB repair, for example BRCAl or BRCA2 deficient cancers, may include, for example, DNA cross-linking agents such as mitomycin C, cisplatin or carboplatin.
Other aspects of the invention relate to the use of an inhibitor of
HR dependent DNA DSB repair in the treatment of a cancer that is deficient in base excision repair.
A method of treatment of a cancer deficient in base excision repair in an individual may comprise; administering an HR dependent DNA DSB repair pathway inhibitor to said individual.
An HR dependent DNA DSB repair inhibitor may be used in the manufacture of a medicament for use in the treatment of cancer in an individual, wherein said cancer is deficient in base excision repair.
An inhibitor of HR dependent DNA DSB repair may include an inhibitor of one or more of the pathway components set out above. Suitable inhibitors include ATM inhibitors.
An ATM inhibitor may, for example, be a compound of formula I:
R 1 3
R 0) N
Np oy ’ ‘
Y or an isomer, salt, solvate, chemically protected form, or prodrug thereof, wherein:
Y is either 0 or 8S; .
R! and R? are independently hydrogen, an optionally substituted Cj.; alkyl group, Cj. heterocyclyl group, or Cs_y, aryl group, or may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; and
R® is a phenyl group attached to an optionally substituted Cs.z carboaryl group by an ether or thioether bridge, the phenyl group and optionally substituted Cs. carboaryl group being optionally linked by a further bridge group, which is bound adjacent the ether or thioether bridge on both groups so as to form an optionally substituted Cs-; oxygen or sulphur containing heterocycle fused to both the phenyl group and the Cs. carboaryl group, the phenyl group being further optionally substituted. ’
Such inhibitors are described in more detail in W003/070726.
Other inhibitors include peptidyl fragments of components of HR dependent DNA DSB repair and encoding nucleic acids as described above.
A cancer condition may be idenfified as deficient in BER activity using a method described above.
Aspects of the present invention will now be illustrated with reference to the accompanying figures described below and experimental exemplification, by way of example and not limitation.
Further aspects and embodiments will be apparent to those of ordinary skill in the art.
Various parameters and features of the invention are set out above.
For the avoidance of doubt, it is stated that all combinations and sub-combinations of these parameters and features are encompassed by the present invention.
All documents mentioned in this specification are hereby incorporated herein by reference.
Figure 1 shows that a reduction in the level of Parpl reduces the viability of BRCAI and BRCA2 mutant cells relative to wild-type cells.
Figure 2 shows the PARP inhibitors KU0058684, KU0058948 and
KU0051529 and their ICss against PARP-1 enzyme activity.
Figures 3 and 4 show clonogenic survival curves of cells exposed to
PARP inhibitors.
Figure 3 shows Brcal wild type (11CO:M), heterozygous (Cre6:A) and deficient (CrelO:e) ES cells under continuous exposure to PARP inhibitors (KU0058684, top; KU0058948, middle; KU0051523, bottom).
Error bars represent standard errors of the mean.
Figure 4 shows Brca2 wild type (D3:M), heterozygous (Cre6:A) and deficient (Cre24:e) ES cells under continuous exposure to PARP inhibitors (KU0058684, top; KU0058948, middle; KU0051529, bottom).
Error bars represent standard errors of the mean.
Figures 5 and 6 show clonogenic survival curves after 1, 4 and 24 hour timed exposures to KU0058684.
Figure 5 shows Brcal wild type (11CO:M), heterozygous (Cre6:A) and deficient (CrelQ:e) ES cells after 1 (top), 4 (middle) and 24 hour (right) timed exposures to KU0058684. Error bars represent standard errors of the mean.
Figure 6 shows Brca2 wild type (D3:M), heterozygous (Cre6:4) and deficient (Cre24:e) ES cells after 1 (top), 4 (middle) and 24 hour (right) timed exposures to KU0058684. Error bars represent standard errors of the mean.
Figures 7 and 8 show that PARP inhibition in BRCA-1 and BRCA-2 mutant cells treated with PARP inhibitor resulted in enhanced G2/M arrest.
Figure 7 shows Brcal wild type (11CO:top) and mutant (CrelO:bottom) cells treated with KU0058684 for 24h at 0 nM (left), 10nM (middle) or 1luM (right) and analysed by FACS.
Figure 8 shows Brca2 wild type (D3) and mutant (Cre24) cells treated with KU0058684 for 24h at 0 nM (left), 10nM (middle) or 1luM (right) and analysed by FACS.
Figure 9 shows a quantitative analysis of Rad51 foci formation induced by PARP inhibition in wild-type cells but not in Brcal or
Brca2 defective cells.
Figure 10 shows a neutral comet analysis of BRCA2-/- VC8 and BRCA2 complemented VC8-BAC. KUO0058684 (1uM) treatment for 30 hours induces a significant increase in DNA DSBs as judged by an increase in tail moment in the BRCA2-~/- cells whilst no significant increase in tail moment is observed in the BRCA2 complemented line. Average data from 3 independent experiments is shown +/- SEM, with 50 comets being scored for tail moment in each experiment.
Figure 11 shows a possible model for the selective effects of PARP inhibition on BRCAl and BRCAZ mutant cells.
Figures 12 and 13 show phospho-histone H3 FACS data for ES cells
Figure 12 shows phospho-histone H3 FACS data for Brcal wild type (11CO:top) and mutant (Crell:) ES cells and Brca2 wild type (D3) and mutant (Cre24) cells treated with KU0058684 for 24h at 0 nM (left), 10nM (middle) or 1uM (right) and analysed by FACS.
Figure 13 shows phospho-histone H3 FACS for VC8 and VCBBAC cells treated with OpM, 100uM, 1nM and 10nM (left to right, respectively)
KU0058684 for 24h.
Figures 14 and 15 show an analysis of the effects of PARP inhibition in other cells lacking BRCAl and BRCA2 function.
Figure 14 shows clonogenic survival curves of Brca2 deficient (V-
C8:M) and complemented (V-C8 BAC+:A) cells under continuous exposure to PARP inhibitors (KU0058684: top, KU0058948: middle and KU0051529: , © bottom).
Figure 15 shows clonogenic survival curves of Brca2 deficient (V-
C8:M) and complemented (V-C8 BAC+:4) cells after 1 hour (top), 4 hour (middle) and 24 hour (bottom) timed exposures to KU0058684.
Erroxr bars represent standard errors of the mean.
Figure 16 shows tumour formation in ES xenografts and the effect of treatment with KU0058684; dotted line - wild type with vehicle, bold solid line - wild type with drug KU0058684, solid line - Brca2 deficient with vehicle, dashed line - Brca2 deficient with
KU0058684.
Figure 17 shows clonal survival curves of BRCAl wild-type (MCF7- scrambled) and BRCAl silenced (MCF7-3.23) cells under continuous exposure to a range of concentrations of the PARP inhibitor
KU0058684 for 12-14 days. Log concentration of inhibitor is plotted against log surviving fraction of cells. Error bars represent standard errors of the mean.
Figure 18 shows clonal survival curves of BRCAl wild-type (MCF7- scrambled) and BRCALl silenced (MCF7-3.23) cells under continuous exposure to a range of concentrations of PARP inhibitor KU0051529 for 12-14 days. Log concentration of inhibitor is plotted against log surviving fraction of cells. Error bars represent standard errors of the mean.
Materials and Methods
RNA interference
Gene-specific pSUPER (T. R. Brummelkamp et al Science 296, 550-3 (2002) ) constructs were generated expressing the following RNAL target sequences: (i) mouse Parpl 5'-GCGGAGUACGCCAAGUCCA-3' (ii) scrambled control 5'- CAUGCCUGAUCCGCUAGUC-3'.
A 1.6 kb fragment containing the CMV IE promoter and eCFP (enhanced cyan fluorescent protein) was subcloned from pECFP-Mito (Invitrogen) into the Sapl site of the resultant pSUPER constructs, generating
PSUPER-eCFP-Parpl and pSUPER-eCFP-control. D3 ES cells were transfected with these plasmids using Lipofectamine 2000 (Invitrogen) according to the manufacturers instructions. Forty- eight hours after transfection, total cell lysates were generated using a buffer composed of 20 mM Tris pH 8, 200 mM NaCl, 1 mM EDTA, 0.5% (v/v) NP40, 10 % (v/v) glycerol and protease inhibitors. 30 pg of each lysate was electrophoresed on Bis-Tris Acetate Acrylamide
Pre Cast Gels (Novex) and blotted onto Trans-Blot Nitrocellulose (Biorad) . Blots were probed with either Rabbit polyclonal anti-PARP- 1 antibody (Cell Signalling, Cat No.S8542) or Rabbit anti-GFP/CFP antiserum (Invitrogen, Cat. No. R970-01), followed by a secondary hybridization with anti-rabbit IgG-HRP with subsequent chemiluminescent detection using ECL™ (Amersham, UK).
Small molecule inhibitors of PARP:
PARP inhibitors were synthesized as described in W002/36576.
Chemical inhibitors were dissolved in DMSO at 10mM and stored at - 20°C in the dark.
Cell Lines
VC8 cells and the mouse Brca2 BAC complemented derivatives were as described in M. Kraakman-van der 2Zwet et al., Mol Cell Biol 22, 669- 79 (2002) ). ES cells defective in Brca2 function have been described previously (Tutt et al. (2002) EMBO Rep 3, 255-60). The construction of ES cells defective in Brcal will be described elsewhere but have previously been validated (Foray et al. (2003) Embo J 22 2860-71).
HBL100 cells were transfected with a pSUPER BRCAl RNAi plasmid and selected with geneticin for 3 weeks. Clones were selected on the basis of their BRCAl expression, as analysed by Northern blot.
Clonogenic Assays
For measurement of sensitivity to Parpl RNA knockdown, ES cells maintained on tissue culture dishes coated with 0.1% gelatin were transfected as above, with either pSUPER-eCFP~Parpl or pSUPER-eCFP- control along with a vector expressing resistance to the antibiotic, blasticidin (pEF-Bsd, Invitrogen). Twenty-four hours after transfection, cells were trypsinised and seeded in 6-well plates.
Forty-eight hours post-transfection, treatment with blasticidin was commenced and cells were re-fed every three days. After 10-14 days, cells were washed with PBS, fixed in methanol and stained with crystal violet. Colonies containing greater than approximately 50 cells were counted.
For measurement of sensitivity to chemical inhibitors, cell cultures in exponential growth were trypsinised and seeded at various densities in 6-well plates onto Mitomycin C inactivated mouse embryonic fibroblasts and where appropriate treated with inhibitors after 18h. For continuous exposure, cells were re-fed every 4 days with fresh medium and inhibitor. For timed exposures, inhibitor was added for the specified period then cells were washed and re-fed with fresh medium. After 10-14 days, cells were washed with PBS, fixed in methanol and stained with crystal violet. Colonies containing greater than approximately 50 cells were counted.
Experiments were performed at least three times in triplicate.
FACS Analysis
For DNA content measurement, cells were fixed in 70% ethanol, incubated with Rnase A and propidium iodide (PI) and analysed with a
FACSCalibur (Becton Dickinson). For phospho-Histone H3 analysis, cells were fixed in 70% ethanol, permeabilised with 0.25% triton X- 100, incubated with anti-phospho-histone H3 antibody (Upstate
Biotechnology) for 3 hours, and then with FITC-anti rabbit IgG (Serotec) for 30 minutes. Processing for FACS analysis was as above.
Apoptotic Analysis
Cells were trypsinised, retaining both culture supernatant and wash medium. These were pooled and the cells washed in cold PBS-A before resuspension at 1x10° cells/ml in binding buffer (10mM HEPES, 140mM
NaCl, 2.5mM CaCl, (pH7.4)). 100pl suspension was incubated in the dark with 5pl Annexin V-FITC (BD Biosciences)/ 0.1lug propidium iodide for 15 mins at room temperature, 400pl binding buffer added and analysed immediately on a FACS Calibur (BD Biosciences).
Rad 51 focus formation
ES cells were cultured for 48h in various concentrations of PARP inhibitor fixed in 4% paraformaldehyde in PBS and permeabilised with 0.2% Triton X100 in PBS. Cells were stained with a 1:100 dilution of rabbit anti-RadS51 ployclonal antibody (Ab 551922, BD-Pharmingen,
Oxford, UK). After washing, the primary antibody was visualised with
Alexa Fluor-555 goat anti-rabbit IgG (Alexa) and nuclei with TO-PRO- 3 iodide (Molecular Probes). Rad51 foci were visualised with and quantified using a Leica TCS-SP2 confocal microscope.
Comet assay
VC8 and VCB-BAC cells were plated 24 hours prior to treatment with 1
MM KU0058684 for 30 hours. All further work was carried out in the dark. Cells were washed with and scraped into PBS prior to Comet analysis as described (Lemay and Wood, 1999). Cells suspended in
LMP agarose (0.5% in PBS) were spread onto Comet slides (Trevigen,
Gaithersburg) and placed at 4 C until set, prior to lysis for 45 mins in 2.5M NaCl, 100mM EDTA, 10mM Tris Base, 1% sodium lauryl sarcosinate, 0.01%Triton X-100. Slides were transferred to TBE for mins prior to electrophoresis at 18V for 15 mins. Slides were then fixed in 100% ethanol for 5 mins and air dried before the addition of SYBR green dye and visualisation by epifluorescence using fluorescien filters (Nikon). Comets were analysed using the
Comet software module of the Lucia G imaging package as supplied by
Nikon. 50 comets per data point were examined for each of three independent experiments and the mean tail moment calculated.
Mitotic Chromosome analysis
ES cells were seeded onto gelatin, treated for 24 hours with chemical inhibitors, followed by colcemid treatment for 1 hour.
Cells were harvested, fixed, dropped onto slides, dried and stained with DAPI before chromosome analysis under a microscope.
ES cell xenografts and treatment with KU0058684
ES cell derived tumours (teratomas) were produced by subcutaneous injection of 2 x 10° ES cells into 6-8 week athymic BALB/c nude (nu/nu) mice. Twenty mice were injected with Brca2 deficient ES cells and an identical cohort with isogenic wild type cells. Two days after cell injection, treatment with KU0058684 or vehicle was initiated. For three consecutive days, two intraperitoneal doses of
KU0058684 (or vehicle) were administered, six hour apart, each at a dosage of 15mg/kg animal. This treatment was then stopped for five days and then reinitiated (as before) for another three consecutive days. Growth of tumours was monitored from a minimum volume of 0.3cm®. The data in figure 16 represents two separate experiments invelving in total 40 animals.
Production of BRCA1l cell-deficient line
The MCF7 scrambled and MCF7-3.23 cell lines were generated by stable transfection of MCF7 mammary adenocarcinoma cells with gene specific pSUPER constructs. Gene specific pSUPER constructs were generated expressing the following RNAi target sequences: (i) human BRCAl 5'-
GGAACCTGTCTCCACAAAG-3’ (ii) scrambled control 5'-
CATGCCTGATCCGCTAGTC-3'. A 1.8kb fragment containing the human EFla promoter and the blasticidin resistance gene (bsd) was subcloned from pEFBsd (Invitrogen) into the Sapl site of the resultant pSUPER constructs, generated pSUPER-Bsd-BRCA1l and pSUPER-Bsd-scrambled.
MCF7 cells were transfected with these plasmids using FuGene6 (Roche) according to the manufacturers instructions. After selection in blasticidin, resistant clones were assessed by real time PCR for silencing of BRCAI mRNA (Egawa et al Oncology. 2001; 61(4): 293-8; Egawa et al Int J Cancer. 2001 Jul 20;95(4):255-9).
Clones with reduced levels of BRCAIl mRNA were cultured (under ’ blasticidin selection) over 8 passages and the real-time assay repeated. Cell line MCF7-3.23 was shown to have only 30% expression of BRCAl compared to MCF7 clones possessing the construct pSUPER-
Bsd-scrambled.
Results
Reduction of Parpl protein levels by SiRNA
A plasmid (pSUPER—eCFP-Parpl) expressing a Parpl specific siRNA under the control of the Hl promoter (T. R. Brummelkamp et al,
Science 295, 550-3 (2002)) and Enhanced Cyan Fluorescent Protein (eCFP) under the control of the CMV IE promoter was transfected into
D3 mouse embryonic stem cells. As a control, a plasmid expressing an unrelated scrambled siRNA, pSUPER-eCFP-control was separately transfected. Forty-eight hours after transfection, cell lysates were prepared and analysed by western blotting. Blots were probed with either a polyclonal anti-PARP-1 antibody or an anti-GFP/CFP antiserum.
Levels of PARP1l in the Parpl specific siRNA expressing cells were observed to be much lower than PARP1 levels in the control cells.
Levels of eCFP were similar in both Parpl siRNA expressing and control cells.
Reduction in the viability of BRCAl and BRCAZ2 deficient cells after
Parpl-specific siRNA knockdown.
Wild type, Brcal™”’™ and Brca2™” mouse embryonic stem (ES) cells were transfected with either pSUPER-eCFP-Parpl or pSUPER-eCFP-control together with a blasticidin resistance-encoding plasmid pEF-Bsd in a 10:1 ratio. Blasticidin resistance clones were selected and quantitated. The results are shown in Figure 1 plotted as the number of colonies after transfection of pSUPER-eCFP-Parpl relative to the } number after transfection of pSUPER-eCFP-control. Error bars are equal to one standard deviation around the mean.
After correction for transfection efficiency using the control siRNA, it was apparent that the survival of both Brcal and Brca2 deficient ES cells was considerably reduced when the expression of
Parpl was inhibited.
Reduction in the viability of BRCAl and BRCA2 deficient cells after chemical PARP Inhibitors
Chemical inhibitors of Parp activity were employed to confirm the selective inhibition of Brcal and Brca2 deficient cells observed above, Two different PARP inhibitors, KU0058684, KU0058948 and a weakly active but chemically related compound KU0051529 were used (Fig. 2). These novel PARP inhibitors are based around a phthalazin-
l-one core and are competitive inhibitors with respect to the PARP substrate NAD'. KU0058684 and KU0058948 are potent and specific inhibitors of the poly (ADP-ribose) polymerase activity of the proteins PARP-1 and PARP-2 and do not inhibit vault PARP, tankyrase or PARP-3 at concentrations up to 1lpuM. Conversely, KU0051529 is ~250x less effective in the inhibition of these enzymes despite being chemically related.
KU0058684, KU0058948 and KU0051529 were used to probe the sensitivity of cells deficient in Brcal or Brca2 to the inhibition of PARP activity. Clonogenic assays showed that both Brcal and Brca2 deficient cell lines were extremely sensitive to KU0058684 and
KU0058948 compared to otherwise isogenic cells (Fig. 3, 4). The SF50 (dosage at which 50% of cells survived) for KU0058684 was 3.5 x 10°°M for Brcal and 1.5 x 107% for Brca2; for wild-type cells this was around 3.5 x 10°®M. This represents factors of 57-fold and 133-fold enhanced sensitivity for Brcal and Brca2 mutant cells respectively compared to wild-type. Similar results were obtained with chinese hamster ovary cells deficient in Brca2, which showed a greater than 1000-fold enhanced sensitivity compared to a Brca2-complemented derivative (Figs 14 and 15). The sensitivity of Brcal and Brca?2 mutant cells to KU0058948 was even greater than that of KU0058684.
In contrast, KU0051522 had no selective effect on cells lacking wild-type Brcal or Brca2 compared to wild-type cells. This, in conjunction with the siRNA data, demonstrates that the mechanism of sensitivity is specifically through inhibition of PARP. Notably none of the inhibitors had any selective effect on cells heterozygous for Brcal or Breca2 mutation.
Time course dependence of the effects on KU0058684 on clonogenic survival of Brcal and Brca2 deficient cells
Cells were exposed to different concentrations of KU0058684 for defined periods of time. The inhibitor was then removed and the effects measured using a clonogenic assay. The inhibitory effects of KU0058684 on clonal growth were apparent after a relatively short exposure time, 4h, and were essentially complete by 24h exposure (Figure 5 and 6). The effects of PARP inhibition were found to be irreversible as a short exposure followed by 10-14 days in the absence of the inhibitor prevents growth.
Effect of PARP inhibition on cell cycle arrest
FACS analysis was used to determine whether PARP inhibition resulted in cell cycle arrest. Cells were exposed with KUC058684 for various periods then labelled with BrdU and the proportion of cells in each phase of the cell cycle. The results are shown in Figures 7 and 8.
KU0058684 was observed to elicit a profound arrest of cells with a tetraploid DNA content indicating arrest in G, or M phase of the cell cycle. To further characterise this arrest, cells were analysed for both DNA content and for phosphorylated Histone H3, an M phase marker. To further characterise this arrest, cells were analysed for both DNA content and for phosphorylated Histone H3, an M phase marker (Figures 12 and 13). The majority of arrested cells did not label with anti-phospho histone H3 antibodies indicating that the majority of cells were arrested in G2.
Rad51 Foci Formation
One hallmark of Brca-dependent double-strand break repair is the formation of foci in the nucleus containing Rad51. The ability of
KU0058684 to elicit Rad51 foci in wild-type and in Brcal and Brca2 deficient cells was investigated.
Wild-type, and Brcal and Brca2 defective ES cells were exposed to differing concentrations of KU0058684 for 48 hours. Cells were then fixed and stained for RAD51 foci as described by Tarsounas (Tarsounas M et al Oncogene. 2003 22(8):1115-23).
In wild-type ES cells, KU0058684 caused Rad51 foci formation in a dose-dependent fashion (Figure 9). In contrast, no foci were induced in Brcal or Brca2 deficient cells. This latter finding is consistent with previous observations that DNA damaging agents cannot cause
Rad51 focus formation in Brcal or Brca2 deficient cells.
KU0058684 is therefore shown to induce lesions, such as double- strand DNA breaks or lesions that degenerate into double-strand DNA breaks, which are repaired by a complex that involves Rad51 and which requires Brcal and Brca2. Importantly, KU0051529 did not induce Radb51 focus formation at comparable doses, emphasizing the specificity of mechanism of sensitisation.
Comet Assays
To determine whether inhibition of PARP activity leads to the production of DNA double-strand breaks, neutral comet assays were performed on Brca2 mutant cells and their isogenic counterparts. The results are shown in Figure 10. After a 30 hour exposure to 1uM
KU0058684, there was a 4.7 fold increase in the tail moment of the
Brca2 deficient VC8 cells and no significant increase in tail moment for the complemented VCB8-BAC line. This result shows that DNA double strand breaks induced by the PARPi are left unrepaired in the
Brca2 deficient line.
Mitotic chromosome analysis
Examination of mitotic chromosomes of Brcal and Brca2 deficient cells revealed that KU0058684 treatment resulted in frequent major aberrations. These included chromatid breaks and tri-radial and quadri-radial chromosomes. These phenotypes provide indication of a failure to repair double-strand breaks by sister chromatid gene conversion and the elevated use of alternative error-prone pathways.
ES cell xenografts and treatment with KU0O058684
Isogenic and Brca2 deficient ES cell derived tumours (teratomas) were produced in athymic BALB/c nude (nu/nu) mice as described above.
The effect of KU0058684 on the growth of wild-type and Brca2 deficient xengraft tumours was measured and the results shown in
Figure 16.
KU0058684 was observed to dramatically reduce the growth of Brca2 deficient tumours relative to wild-type tumours.
Effect of PARP Inhibition in BRCAI cell-deficient lines
The MCF7-scrambled and MCF7~3.23 cell lines were produced as described above. MCF7-3.23 was found to have 30% expression of BRCAl compared to MCF7-scrambled.
Both MCF7-scrambled and MCF7-3.23 cells were treated with KU0058684 and KU0051529 and the survival of cells determined (figures 17 and 18). KU0058684 is a potent PARP inhibitor whereas KU0051529 is less effective.
Neither MCF7-scrambled nor MCF7-3.23 cells displayed significant sensitivity to KU0051529 (figure 18). However both cell lines were sensitive to KUQ058684.
MCF7-3.23 cells were shown to be significantly more sensitive to
KU0058684 than MCF7-scrambled cells.
Interaction of PARP with the HR dependent DNA DSB pathway
Without limiting the scope of the invention in any way, one possible model for interaction between PARP and the HR dependent DNA DSB pathway is shown in Figure 11.
DNA single-strand breaks (SSB) form due to oxidative damage and its repair. Inhibition of Parp-1 PAR polymerase activity prevents the recruitment of the XRCC1l scaffold protein and subsequent SSB gap filling by DNA polymerises (figure 113).
Large numbers of SSBs persist and are encountered by DNA replication forks. The absence of a template strand at the SSB leads to a DSB and may, dependent on position, cause replication fork collapse (figure 11B).
The proximity of an undamaged sister chromatid template allows the invasion of the sister chromatid by RADS51 coated single stranded DNA filament and initiation of sister chromatid recombination repair.
This process is dependent on BRCAl and BRCA2 and is associated with the formation of multiple nuclear foci of RAD51. Collapsed replication forks can be restarted by a similar mechanism (Figure i1c).
When Holliday junctions at recombination intermediates are resolved, a sister chromatid exchange (SCE) may occur. The excess number of
SSBs encountered by replication forks during Parp-1 inhibition leads to an increase in SCEs (Figure 11D).
In the absence of functional BRCAl or BRCA2, RAD51 focus formation and sister chromatid recombination are severely impaired. The excess unrepaired SS5Bs form DNA DSBs during DNA replication but sister chromatid recombination does not occur. They remain unrepaired as chromatid breaks or are repaired by error prone RAD51 independent mechanisms causing complex chromosome rearrangements. These cells arrest when they encounter the G2/M DNA damage checkpoint and permanently arrest or apoptose (Figure 11E).
RNAi data provided herein, along with the observation that KU0051529 was ineffective, demonstrate that PARP inhibition is responsible for the sensitisation effects observed.
PARP inhibition induces lesions that are normally repaired by sister chromatid exchange (SCE) (Wang 2Q, et al (1997) Genes Dev. Vol. 11(18):2347-58 and ‘From DNA damage and stress signalling to cell death’ G. de Murcia and S. Shall eds. Oxford University Press
(2000) ). PARP inhibition is known to increase SCE, with no concomitant increase in gene conversion of DSBs and therefore no global increase in the Rad51-dependent recombination pathway (Schultz N et al 2003, Nucleic Acids Research; vol.31 (17): 4959- 4964) .
The synthetic lethality approach descriled herein may be useful both in the treatment of a) in tumours in BRCA carriers b) in tumours where other components of HR dependent DNA DSB repair are defective.
Although differences have been described in the age of onset and pathology of tumours in carriers of BRCA mutations, treatment is the same at present as for patients with sporadic disease. The present invention provides a new approach for these tumours is described herein.
Significantly, no heterozygous effect was observed. This is important for the therapeutic use of the described methods in heteozygous carriers of mutations in the HR dependent DNA DSB repair pathway, including, for example BRCAl/2 mutations.
Claims (1)
- Claims:1. Use of a poly (ADP-ribose) polymerase (PARP) inhibitor in the manufacture of a medicament for use in a method of treatment of cancer deficient in HR dependent DNA DSB repair pathway in an individual comprising, identifying a cancer condition in an individual as deficient in HR dependent DNA DSB repair and administering the PARP inhibitor to said individual. tT 2. Use according to claim 1 wherein said cancer comprises one or more cancer cells having a reduced or abrogated ability to repair DNA DSB by HR relative to normal cells.3. Use according to claim 1 or 2 wherein said cancer is identified as a HR dependent DNA DSB repair deficient cancer by determining the HR dependent DNA DSB repair activity of cancer cells from the individual relative to normal cells.4. Use according to claim 3 wherein the activity of the HR dependent DNA DSB repair pathway is determined in the cancer : cells by measuring the formation of foci containing Rad51 in the nucleus in response to DNA damaging agents or PARP inhibitors.5. Use according to claim 1 or claim 2 wherein said cancer is identified as an HR dependent DSB repair deficient cancer by determining the presence in cancer cells from the individual of one or more mutations or polymorphisms in a nucleic acid sequence encoding a component of the HR dependent DNA DSB repair pathway.6. Use according to any one of claims 1 to 5 wherein said cancer cells have a BRCAl or BRCA2 deficient phenotype.7. Use according to claim 6 wherein said cancer cells are deficient in BRCAl or BRCAZ. AMENDED SHEET) 8. Use according to claim 7 wherein said cancer cells are homozygous for a mutation in BRCAl or BRCA2.9. Use according to any one of claims 1 to 5 wherein said individual is heterozygous for a mutation in a gene encoding a component of the HR dependent DNA DSB repair pathway.10. Use according to claim 9 wherein said individual is heterozygous for a mutation in BRCAl and/or BRCA2.11. Use according to any one of the preceding claims wherein said cancer is breast, ovary, pancreas or prostate cancer.12. Use according to any one of claims 1 to 11 wherein the PARP inhibitor is a peptide fragment of PARP.13. Use according to any one of claims 1 to 11 wherein the "7° PARP inhibitor is a nucleic acid encoding all or part of the - --- - amino acid sequence of PARP, or the complement thereof. :15. Use according to claim any one of claims 1 to 11 wherein said PARP inhibitor is selected from the group consisting of nicotinamides, benzamides, isoquinolinones, dihydroisoquinolinones, benzimidazoles, indoles, phthalazin- 1 (2H) -ones, quinazolinones, isoindolinones, phenanthridines, benzopyrones, unsaturated hydroximic acid derivatives, caffeine, theophylline, and thymidine, and analogues and derivatives thereof.16. Use according to claim 15 wherein said PARP inhibitor is a phthalazin-1(2H) -one or an analogue or derivative thereof.17. Use according to any one of claims 1 to 16 wherein said medicament further comprises a DNA damaging chemotherapeutic agent. AMENDED SHEET18. Use according to any one of claims 1 to 16 wherein said treatment further comprises administration of a DNA damaging chemotherapeutic agent.19. A PARP inhibitor for use in a method of treatment of cancer deficient in HR dependent DNA DSB repair pathway in an individual comprising, identifying a cancer condition in an individual as deficient in HR dependent DNA DSB repair and administering the PARP inhibitor to said individual.20. A PARP inhibitor according to claim 19 wherein said cancer cell has a reduced or abrogated ability to repair DNA DSB by HR relative to normal cells.21. A PARP inhibitor according to claim 19 or 20 wherein said cancer is identified as a HR dependent DNA DSB repair deficient cancer by determining the HR dependent DNA DSB repair activity of cancer cells from the individual relative to normal cells.22. A PARP inhibitor according to claim 21 wherein the activity of the HR dependent DNA DSB repair pathway is determined in the cancer cells by measuring the formation of foci containing Rad51 in the nucleus in response to DNA : damaging agents or PARP inhibitors.23. A PARP inhibitor according to claim 19 or claim 20 wherein said cancer is identified as an HR dependent DSB repair deficient cancer by determining the presence in cancer cells from the individual of one or more mutations or : polymorphisms in a nucleic acid sequence encoding a component of the HR dependent DNA DSB repair pathway.24. A PARP inhibitor according to any one of claims 19 to 23 wherein said cancer cells have a BRCAl or BRCA2 deficient phenotype. AMENDED SHEET25. A PARP inhibitor according to claim 24 wherein said cancer cells are deficient in BRCAl or BRCA2.26. A PARP inhibitor according to claim 25 wherein said cancer cells are homozygous for a mutation in BRCAl or BRCAZ2.27. A PARP inhibitor according to any one of claims 19 to 26 wherein said individual is heterozygous for a mutation in a gene encoding a component of the HR dependent DNA DSB repair pathway. :28. A PARP inhibitor according to claim 27 wherein said individual is heterozygous for a mutation in BRCAl and/or BRCA2. : 29. A PARP inhibitor according to any one of claims 19 to 28 ‘ wherein said cancer is breast, ovary, pancreas or prostate cancer.30. A PARP inhibitor according to any one of claims 19 to 29 wherein the PARP inhibitor is a peptide fragment of PARP.31. A PARP inhibitor according to any one of claims 19 to 29 : wherein the PARP inhibitor is a nucleic acid encoding all or part of the amino acid sequence of PARP, or the complement thereof.32. A PARP inhibitor according to any one of claims 19 to 30 wherein said PARP inhibitor is selected from the group consisting of nicotinamides, benzamides, isoquinolinones, dihydroisoquinolinones, benzimidazoles, indoles, phthalazin- 1 (2H) -ones, quinazolinones, isoindolinones, phenanthridines, benzopyrones, unsaturated hydroximic acid derivatives, caffeine, theophylline, and thymidine, and analogues and derivatives thereof. AMENDED SHEET33. A PARP inhibitor according to claim 32 wherein said PARP inhibitor is a phthalazin-1(2H)-one or an analogue Or derivative thereof.34. A PARP inhibitor according to any one of claims 19 to 33 wherein said treatment further comprises administration of a DNA damaging chemotherapeutic agent. 35, A method of assessing an individual having a cancer condition comprising; identifying a cancer cell obtained from the individual as deficient in HR dependent DNA DSB repair relative to normal cells, and;providing a PARP inhibitor suitable for administration to said individual.36. A method of assessing the activity of the HR dependent DNA DSB repair pathway in a cancer condition of an individual : comprising; contacting a PARP inhibitor with a sample of cancer cells obtained from the individual having the cancer - condition, and; determining the amount of cell death in said sample.37. A method of predicting the response of a cancer condition in an individual to a treatment targeting a cancer deficient in HR dependent DNA DSB repair comprising; contacting a PARP inhibitor with a sample of cancer cells obtained from the individual having the cancer condition, and; determining the amount of cell death in said sample.38. A method according to any one of claims 35 to 37 wherein the PARP inhibitor is a peptide fragment of PARP.39. A method according to any one of claims 35 to 37 wherein the PARP inhibitor is a nucleic acid encoding all or part of the amino acid sequence of PARP, or the complement thereof. AMENDED SHEET40. A method according to any one of claims 35 to 37 wherein said PARP inhibitor is selected from the group consisting of nicotinamides, benzamides, isoquinolinones, dihydroisoquinolinones, benzimidazoles, indoles, phthalazin- 1 (2H) -ones, quinazolinones, isoindolinones, phenanthridines, benzopyrones, unsaturated hydroximic acid derivatives, : caffeine, theophylline, and thymidine, and analogues and derivatives thereof.41. A method according to claim 40 wherein said PARP inhibitor is a phthalazin-1(2H) -one or an analogue or . derivative thereof.42. A method according to any one of claims 35 to 41 comprising identifying the cancer as deficient in HR dependent DNA DSB repair43. A method according to any one of claims 35 to 42 wherein a the cancer is identified as having a BRCAl or BRCA2 deficient Co phenotype. AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52624403P | 2003-12-01 | 2003-12-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200605340B true ZA200605340B (en) | 2007-12-27 |
Family
ID=37674883
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200605340A ZA200605340B (en) | 2003-12-01 | 2006-06-28 | DNA damage repair inhibitors for treatment of cancer |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN1905864B (en) |
ZA (1) | ZA200605340B (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102372706A (en) * | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | Phthalazinone derivative, its preparation method and application in medicament |
KR20130115250A (en) * | 2010-09-15 | 2013-10-21 | 알막 다이아그노스틱스 리미티드 | Molecular diagnostic test for cancer |
RU2665952C2 (en) | 2011-07-22 | 2018-09-05 | Пасилекс Фармасьютикалз Инк. | Synthetic lethality and the treatment of cancer |
CN103130723B (en) | 2011-11-30 | 2015-01-14 | 成都地奥制药集团有限公司 | Poly (aenosine diphosphate glucose pyrophospheralase (ADP)-ribose) polymerase inhibitor |
CN102898377B (en) * | 2012-02-14 | 2016-01-20 | 南京圣和药业股份有限公司 | One class phthalazinone derivatives and uses thereof |
EP3543353A1 (en) * | 2013-09-23 | 2019-09-25 | The University of Chicago | Methods and compositions relating to cancer therapy with dna damaging agents |
ES2964607T3 (en) | 2015-07-17 | 2024-04-08 | Pacylex Pharmaceuticals Inc | Epigenetic silencing of NMT2 |
MX2018014366A (en) * | 2016-05-27 | 2019-04-11 | Synthex Inc | Protein interfaces. |
WO2019104244A1 (en) | 2017-11-22 | 2019-05-31 | Synthex, Inc. | Peptides for inhibiting rad51 |
CN108358850B (en) * | 2018-02-11 | 2021-01-26 | 中国药科大学 | PARP-1 and Tankyrase1/2 multi-target inhibitor, preparation method and application thereof |
CN116036083B (en) * | 2023-04-03 | 2023-06-02 | 江西省林业科学院 | Application of pyranoquinolinone compounds in preparation of medicines for treating cervical cancer |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7122679B2 (en) * | 2000-05-09 | 2006-10-17 | Cephalon, Inc. | Multicyclic compounds and the use thereof |
CN100400518C (en) * | 2000-10-30 | 2008-07-09 | 库多斯药物有限公司 | Phthalazinone derivatives |
JP2004528376A (en) * | 2001-05-08 | 2004-09-16 | クドス ファーマシューティカルズ リミテッド | Isoquinolinone derivatives as PARP inhibitors |
JP4500161B2 (en) * | 2002-04-30 | 2010-07-14 | クドス ファーマシューティカルズ リミテッド | Phthalazinone derivatives |
-
2004
- 2004-11-30 CN CN2004800408316A patent/CN1905864B/en active Active
-
2006
- 2006-06-28 ZA ZA200605340A patent/ZA200605340B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN1905864A (en) | 2007-01-31 |
CN1905864B (en) | 2011-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210244706A1 (en) | DNA Damage Repair Inhibitors for Treatment of Cancer | |
ZA200605340B (en) | DNA damage repair inhibitors for treatment of cancer | |
Peralta-Leal et al. | PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases | |
Murata et al. | Predictors and modulators of synthetic lethality: an update on PARP inhibitors and personalized medicine | |
BRPI0412909B1 (en) | Use of a poly(adp-ribose) polymerase 1 (parp-1) inhibitor for the manufacture of a drug for the treatment of defective cancer cells in homologous recombination | |
Chen et al. | Increased PARP1‐DNA binding due to autoPARylation inhibition of PARP1 on DNA rather than PARP1‐DNA trapping is correlated with PARP1 inhibitor's cytotoxicity | |
Zhanfeng et al. | Period2 downregulation inhibits glioma cell apoptosis by activating the MDM2-TP53 pathway | |
US20180110777A1 (en) | Method for regulation of telomere length | |
WO2008020180A2 (en) | Methods of increasing the sensitivity of cancer cells to dna damage | |
Celebre | ID1 mediates glioblastoma chemoresistance to temozolomide | |
Williamson | EXPLOITING THE SYNTHETIC LETHAL INTERACTION OF ATM AND PARP | |
MXPA06000953A (en) | Use of rnai inhibiting parp activtiy for the manufacture of a medicament for the treatment of cancer |